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ABSTRACT 
 
The field of biological sciences has expanded enormously within the last few decades. Developments in 
techniques and instrumentation have allowed biologist to explore biological mechanisms in an 
unprecedented detail. One of the most evolved disciplines is the field of proteomics. In general, proteins 
function in many different biological roles. They serve as structural molecules, in signaling routes mediating 
information in the cell, in intra- and extracellular transport and trafficking as well as in numerous other 
cellular functions. The area of protein research entails the study of all things relating to proteins and their 
functions. These include cellular protein composition, expression changes, protein structure, post-
translational modifications and protein-protein interactions. 
Mass spectrometry (MS) has become one of the key technologies in proteomic research. The relative ease of 
sample handling and automated MS machinery has made proteomic analysis relatively straightforward. Mass 
spectrometers work by measuring the weight of intact proteins or protein-derived peptides. Proteomic MS 
identification is usually done by fragmenting the proteins or peptides in the mass spectrometer and using 
the resulting mass spectral information in identification of peptide sequence. There are two main strategies 
of peptide sequence identification: database dependent and de novo identification. Database dependent 
algorithms utilize known sequence information stored in databases to decipher the peptide amino acid 
sequence of the MS-observed spectra and use that information to predict the protein from which the peptide 
is derived from. On the other hand de novo methods try to construct the peptide sequence solely based on 
the fragmentation patterns of the peptide. The completeness of sequence databases of many species and 
the speed and efficiency of the search engines have made the database dependent search as the main 
method in peptide and protein identification. 
The modern high resolution mass spectrometers along with ultra-performance liquid chromatography have 
enabled the detection of thousands of protein in one single MS run. This, together with advances in MS-
based protein quantification has extended the use of mass spectrometers in discovery type biomarker search. 
Mass spectrometers are able to produce a large amount of data on numerous proteins that can be used to 
detect and quantify differences in patient and control samples. This in turn can be used as starting point for 
more focused validation studies on the acquired data and ultimately lead to useful clinical biomarkers.  
The focus of this study was to utilize and learn mass spectrometric methodologies and to analyze different 
proteomic processes in sample types. We analyzed the protein-protein interactions in Baker´s yeast PSA1 
protein in various points of batch cultivation using database dependent and de novo protein identification 
methods. We showed that the interactome of PSA1 is very dynamic depending on the phase of the 
cultivation. We also showed the limitations and benefits of de novo identification and the combined use of 
both search strategies in improving the confidence of the identifications. In another study using affinity 
purification and mass spectrometry we identified Fibrillin-2 as the binding partner of lung cancer associated 
Gremlin-1 protein. This finding elucidates functions and mechanisms of Gremlin-1 and Fibrillin-2 in malignant 
tissues. In two mass spectrometry-based protein quantification studies we characterized the protein 
concentration changes in human plasma during liver transplantation surgery as well as the effect of excess 
sialic acid production in HEK293 model cell line. In the liver transplantation plasma project we identified 
protein concentration changes in liver in response to the trauma caused by the surgery using label-based 
iTRAQ method. We showed consumption and secretion of several coagulation related proteins within the 
liver suggesting activation of coagulation cascade in the very early phases of the craft reperfusion. In the 
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study of excess sialic acid production we first verified the amounts of sialic acid using mass spectrometry-
based multiple reaction monitoring method. We were able to induce the production of sialic acid to almost 
70-fold compared to control cells. We also monitored the protein abundance changes in sialic acid producing 
cells using label free proteins quantification method identifying 105 changed proteins. We analyzed those 
proteins with several functional enrichment tools revealing modifications in cellular protein transport, 
metabolic and signaling pathways and in remodeling of cellular adherens junctions. Such large scale MS-
analyses using ontology-based tools can significantly aid in deciphering the effect of perturbations to complex 
systems but also reveal novel functional targets for biomarker discovery.  
The results obtained from targeted interaction experiments as well as large scale quantification studies can 
be used as basis for more rigorous investigations on the various subjects in search for potential biomarkers 
for clinical use. The techniques and methods used in the studies also demonstrate the many uses of mass 
spectrometric techniques in several fields of proteomic and biological research. 
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REVIEW OF LITERATURE 
 
Introduction 
In the past two decades mass spectrometry (MS) has become a major workhorse in biological research. 
Especially the field of proteomics, or the characterization of entire protein content of biological samples, has 
benefitted from the increasing sensitivity and resolution of rapidly evolving mass spectrometers1,2. The 
capability of modern mass spectrometers to identify and characterize hundreds of proteins in a single MS 
run has widely expanded our knowledge of the functional organization of the cellular proteomes3. The 
concurrent developments in liquid chromatography (LC) and mass spectrometer technology combined with 
highly sophisticated bioinformatics methods have also increased the use of MS machinery in proteomic 
quantification. This has led to an increase in the usability of mass spectrometers in proteomic biomarker 
discovery and in clinical proteomics4,5. In this Ph.D. project modern mass spectrometric methods were 
utilized in examination of general proteomic events in biological systems and in research for potential 
biomarkers for clinical samples. 
1. Proteomic research 
The term proteome was first coined by Wasinger et al.6 in their study of protein content of Mycoplasma 
genitalium. Thereafter the term proteomics has expanded to include a multitude of protein-related subjects 
such as post-translational modifications (PTM), protein-protein- interactions and cellular protein quantities 
(Figure 1.). The importance of proteomic research has been emphasized by the increasing knowledge of the 
complexity of biological systems and the emergence of system biology view of biological events7,8. The 
classical view of Genes-to-RNA-to-Protein-to-Function has been replaced by an intricate network of space 
and time dependent interactions and regulation of different parts of cellular systems9. 
 
 Figure 1. Different types of 
proteomic research 
Proteomic research can be divided 
into several different subcategories. 
These include analysis of post-
translational modifications, protein-
protein interactions, proteins 
structure determination, changes in 
protein abundances as well as 
functional proteomic network and 
pathway analysis 
 
The complexity of cellular and humoral proteome is immense. In human plasma the protein quantities extend 
over ten orders of magnitude with low levels of cellular leakage proteins to serum albumin constituting over 
50 percent of the entire serum protein content10,11. Similarly, the intracellular proteome can range several 
orders of magnitude depending on the cellular state. Some proteins are expressed transiently at low levels 
Proteome
Post-translational
modifications Protein concentration
changes
Pathways and networks
Protein structure
Protein-protein
interactions
”Interactomics”
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in response to perturbations or at distinct points during cell cycle as others, mainly housekeeping proteins, 
are constantly expressed at high abundance12. 
Post-translational modifications of proteins (PTM) create an additional layer of complexity to biological 
systems. So far more than 160 different mammalian post-translational protein modifications have been 
characterized in over 45000 different sites (24.4.2013)13. Most common of these include phosphorylation of 
serine and threonine, N-glycosylation of asparagine and acetylation of lysine. PTMs modulate cellular 
processes such as signaling cascades, protein-protein interactions, subcellular localization and protein 
degradation14. The PTM status of individual proteins depends on the cellular state. For example, external 
stimuli may activate specific and local signaling routes by phosphorylation a subset of proteins and 
consequent response to the stimuli. After response the phosphoryl groups are removed by phosphatases and 
the signaling route deactivated15. The dynamic nature of different PTMs creates subproteomes of 
differentially modified proteins that further complicate proteomic analysis. 
Proteomic research entails also the study of protein-protein interactions. Similarly to PTMs, physical 
interactions modulate the functions of most proteins. Some proteins are direct constituents of larger 
proteomic machines, such as ribosomal, spliceosome and proteasome proteins, while others exhibit transient 
interactions that briefly regulate the activity of the interacting proteins16,17. The study of interactomics tries 
to elucidate the networks of the interacting proteins and characterize the systemic changes occurring in 
response to perturbations or in diseased states. 
1.1 Principles of proteomic mass spectrometry 
Mass spectrometric analysis of proteins means the characterization of proteins or peptides based on their 
respective masses. There are two main types of analysis in proteomic MS research: top-down and bottom-
up MS analysis. In top-down MS analysis18 intact proteins can used to identify the proteins19, examine the 
post-translational modifications20 of individual proteins or to characterize intact protein complexes21. 
However, the most classical type of analysis is still the analysis of protein derived peptides, or bottom-up 
proteomics22 (Figure 2.). In shotgun protein characterization the proteins are digested to short fragments of 
few kilodalton using proteolytic enzymes. Combined with prefractionation and liquid chromatography 
analysis, shotgun proteomics can identify thousands of proteins from very complex mixtures. The 
applicability of shotgun proteomics has been demonstrated in a wide array of complex proteomic 
experiments including identification and quantification of proteins23 but also in verification of novel genes 
and splice forms24. 
Figure 2. Bottom-up proteomic MS workflow 
The protein sample is first digested with proteolytic enzyme, usually trypsin. Then the sample is fractionated using online 
reverse phase chromatography before analysis with mass spectrometer. The resulting MS spectrum is processed and the 
proteins are identified with search engines. 
1
2
3
Protein
sample
Digestion Fractionation Mass
spectrometry
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In shotgun LC-MS proteomics the peptides are introduced to mass spectrometer by direct coupling of liquid 
chromatography system to the mass spectrometer. The LC system is on-line with MS so that eluting peptides 
are directly injected to MS using electrospray ionization (ESI)25. In the LC-ESI interface the peptides are ionized 
and transferred from liquid to gas phase. After ionization they are transferred through the mass spectrometer 
with ion optics that uses magnetic fields and radiofrequency lenses to guide and select molecules in the mass 
spectrometer. Peptide can also be fragmented in the mass analyzer. The MS fragmentation produces a series 
of short peptides that contain the sequence information needed for identification of the peptide. At the end 
of the mass spectrometer the ions are detected by mass detectors that scan and record the mass spectra of 
the peptides. The result is a peak list of all the detected masses represented as a ratio of the ion mass and its 
accompanying ionization charge (mass/charge = m/z). This peak list of m/z-values can then be imported to 
different bioinformatics search tools that compare the detected peptide masses to computer generated list 
of all possible masses derived from predefined protein database. By matching the detected peptide mass to 
theoretical mass the search programs can reliably and efficiently identify the proteins that are present in the 
analyzed sample. 
1.2 Proteomic sample preparation 
1.2.1 Enzyme digestion 
The modern high end mass spectrometers are able to reliably identify very large peptides or intact proteins, 
but in general the limitations in resolution of most mass spectrometers require that the analyzed molecule 
is not too large and contains adequate number of charges. Therefore prior to shotgun MS analysis the 
proteins must be digested with proteolytic enzymes to yield shorter peptides. This can be done directly to 
sample proteins (in-solution digestion) or after separation steps (one- or two-dimensional gels). Most of the 
commonly used digestion enzymes produce peptides with suitable m/z range and charge for MS analysis. 
There are several different enzymes available for protein digestion for mass spectrometry that have different 
specificities on the digestion site of the protein26. These include Asp-N that cleaves from amino sides of 
asparagine and cysteine, Glu-C cleaving carboxyl side of glutamine and asparagine, and Lys-C and Arg-C that 
cleave from carboxyl sides of lysine and arginine respectively. In order to allow the identification of peptides 
participating in sulfur bridges, the sulfur bonds are usually reduced after digestion and the resulting free 
cysteines alkylated. The most common digestion enzyme used in proteomic research is trypsin. Trypsin 
cleaves proteins after lysine or arginine provided that there are no prolines adjacent to the site27. At acidic 
pH the peptides normally retain one positive charge at the amino group of N-terminus. The addition of 
potential secondary ionization site at the C-terminus by trypsin increases the coverage of mass spectrometric 
fragmentation in MS and subsequent identification of peptides. Trypsin also has the advantage of tolerating 
quite high salt or detergent conditions and is able to penetrate SDS-PAGE matrix in in-gel digestion. 
Additionally there are few commercial trypsins that have been modified to resist autodigestion thus 
simplifying the MS data-analysis. 
1.2.2 Prefractionation of proteomic samples 
Due to the complexity of biological samples the characterization of complex proteomes often requires 
sample fractionation. Even though modern mass spectrometers have a high sensitivity with detection limits 
up to low femto- or even attomolar range, the dynamic range of the MS machinery is limited by ion 
suppression and other matrix effects caused by different physicochemical properties of molecules28. MS 
dynamic range refers to the range of lowest and highest analyte that can be detected by mass spectrometer. 
Current MS instrumentation has a dynamic range approximately 3-4 orders of magnitude depending on the 
used technology29. Another bottleneck in MS analysis of complex mixtures is the duty cycle of MS 
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instrumentation. Due to the inherent constraints of the MS machinery, a large proportion of eluting peptides 
may go undetected by the mass detector30. In order to avoid the constraints in the MS duty cycle and ion 
suppression and to enhance the dynamic range of MS acquisitions, several methods have been developed 
for prefractionate the sample prior to MS analysis. 
1.2.2.1 SDS-PAGE 
Protein separation with SDS-polyacrylamide gels has been one of the main tools in biological research for 
over four decades31. One dimensional gel (1D SDS-PAGE) separates proteins based solely on the respective 
size of the protein. Two dimensional (2-DE) gels separate the proteins first by their isoelectric point and then 
orthogonally by their size32. In MS analysis the gel-separated proteins are excised from the gel, digested 
enzymatically and analyzed with LC-MS. In spite of being one of the most popular preparation methods in 
proteomics, there are some drawbacks using gel-based system in mass spectrometric analysis. These include 
sample loss from processing steps, issues with dynamic range of the sample and compatibility of SDS-PAGE 
protein detection methods with MS analysis33. 
1.2.2.2 Liquid chromatography methods 
Liquid chromatography fractionation is generally used in conjunction with mass spectrometers. LC systems 
offer an unparalleled separation dimension to mass spectrometers by reducing the complexity of the sample 
and by concentrating the individual peptides during elution. Current ultra-pressure LC instrumentation34,35 
with nanoliter flow rates and modern chromatography materials have made it possible to identify several 
hundreds of proteins in one single LC-MS run36. 
Reverse phase (RP) column chromatography is currently the main method of on-line separation of peptides 
in LC-MS analysis. In RP separation the peptides are separated based on their interactions with hydrophilic 
stationary phase of the column. Elution is done by gradients of increasing concentration of non-polar, MS 
compatible solvents in the mobile phase37. Another widely used technology is ion exchange chromatography 
such as strong cation (SCX) and anion (AEX) chromatography. Ion exchange separates molecules by 
interaction between charged side chains of peptides and charged stationary phase. Elution can be done using 
increasing amounts of salts or modifying the pH of the mobile phase. However large concentrations of salts 
interfere with mass spectrometry analysis so SCX is used either off-line or in two dimensional on-line 
separations38,39. 
Similarly to 2-DE gels, LC methods can be used on-line in two dimensions as orthogonal technologies in order 
increase sample fractionation efficiency and separation40. Most commonly used 2D-LC method is 
multidimensional protein identification technique (MudPIT)41. In MudPIT chromatography the peptides are 
first fractionated stepwise with SCX. Eluted peptides are then introduced to RP column where they are 
retained while the salt-containing eluent is washed away. Normal RP separation is then applied to the 
peptides on-line with HPLC. 2D-LC separation can significantly improve the identification efficiency and the 
amount if identified peptides from complex matrices42. Several other methods can be used instead of SCX-
RP43. For example, tandem RP-RP with different pH in both steps has been shown to be a comparable method 
to SCX-RP44. 
1.2.3 Enrichment methods 
RP and SCX are used in global separation of peptides based on the general properties of the amino acid side 
chains. However, there are methods that can be used to enrich a specific subproteomes of complex samples. 
These include post-translational modifications such as phosphorylation and glycans as well as enrichment of 
different organelles. 
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1.2.3.1 Phosphorylation enrichment 
The most common post-translational modification is protein phosphorylation13. A variety of protein functions 
are modulated by addition of phosphate group to serine, threonine or tyrosine side chains. Phosphorylation 
is used in many signaling routes and other processes that are dynamically activated and deactivated and may 
be found in low stoichiometric amounts. For his reason the MS identification requires that the low abundance 
phosphopeptides are enriched and purified from the non-phosphorylated material. The phosphate group 
possesses a high negative charge which can be utilized to enrich the phosphoproteome of samples (Figure 
3.). Currently the most common and sensitive phosphopeptide enrichment material is immobilized titanium 
dioxide (TiO2). Along with modifiers that inhibit binding of nonphosphorylated and acidic peptides, TiO2 can 
be used to enrich phosphopeptides to high degree45. Additionally, TiO2 can be used in on-line 2D-LC-MS 
where phosphopeptides are first enriched with TiO2 column and then fractionated with RP that is directly 
coupled to ESI-MS46. Alternative methods in phosphoproteome enrichment include immobilized metal 
affinity chromatography (IMAC) that captures phosphopeptides by binding of the negatively charged 
phosphates to ferric iron47 or immunopurification of phosphopeptides with antibodies recognizing 
phosphorylated amino acids. 
1.2.3.2 Glycosylation enrichment 
Glycosylation involves addition of distinct glycan structures to mostly cell surface and secreted proteins48. 
The glycosylation pattern is highly versatile with thousands of different glycan structures. Carbohydrate 
binding proteins called lectins recognize and bind specific glycan structures49,50. By attaching the lectin to 
immobilized support the specific glycan containing proteins or peptides can selectively be isolated from non-
glycosylated or uninteresting material (Figure 3.). Additional glycopeptide and glycoprotein enrichment 
methods include size exclusion that separates larger glycan containing peptides from smaller non-
glycosylated material51 and chemical derivatization of glycopeptides52 
 Figure 3. Phosphoprotein and glycoprotein enrichment methods 
Proteins or peptides can be enriched using specific material that binds and 
retains the desired proteins in the support material while the unwanted 
proteins are washed away. Phosphoproteins can be enriched using ferric 
iron (IMAC) or titanium dioxide (TiO2). Specific proteins called lectins that 
bind certain glycan moieties are used in glycoprotein enrichment. 
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1.2.3.3 Organelle enrichment 
In some cases the interesting biological phenomena occur in organelles and other subcellular structures53. 
When analyzing tissues or other cell samples the material is usually lysed by mechanical or chemical means 
to free the contents of the cells. This mixes the contents of the organelles to cytosolic and other proteins 
making the analysis of the organelle impossible54. In order to examine the different subproteomes of these 
structures, they can be enriched prior to analysis. For example, several organelles can be fractionated after 
gentle disruption of plasma membrane and by centrifugation of the lysate in gradients mediums that 
separate the organelles by their density55. Additional enrichment methods such as affinity purification and 
electrophoretic and mechanistic sorting have also been successfully employed in organelle enrichment56. 
1.2.4 Protein complex affinity purification 
The field of interactomics or protein-protein- interaction research has emerged as an important aspect of 
proteomic research57. In order to study the interactions of individual proteins with mass spectrometry, the 
interacting proteins must be purified with their interacting proteins. The strength of physical interactions 
between proteins vary from transient and low affinity to extremely stable. For this reason the optimization 
of the isolation protocol is extremely important58. Inadequate or weak handling may result in extremely high 
unspecific binding masking the true interactors. On the other hand too harsh conditions can remove the low 
affinity partners reducing sensitivity of the protocol.  
The main method in interactomics has been co-immunoprecipitation of proteins (Co-IP) (Figure 4.1). In Co-IP 
the proteins, along with their interacting partners are purified using antibodies against the protein of interest 
coupled to a solid support. The main benefit of Co-IP is that it can be used on all biological material and 
proteins with suitable antibodies. However, some antibodies have a tendency for to bind unspecific proteins 
creating a high background of false positives in Co-IP59.  
An alternative method for Co-IP is affinity-purification mass spectrometry (AP-MS)60. AP-MS uses biochemical 
tags that are genetically inserted to the protein of interest. The tag is chosen so that the tag has a high affinity 
binding partner. By immobilization of the tags binding partner to solid matrix and the introduction of sample 
to the bound matrix, the tagged protein along with its bound interactions partners can be isolated and 
purified61. After elution from the matrix the purified complexes can be easily digested in solution and 
analyzed with MS. Several methods have been developed which use two different affinity tags62,63 (Figure 
4.2). These tandem affinity purification tags (TAP) enable two-staged purification with different washing 
steps removing most of the contaminating unspecific interactions from the sample64. The downside of using 
two washing steps is the potential loss of low affinity and transient binding partners that may be removed by 
the extra sample handling steps62. The power of tandem affinity tags and AP-MS has been proven by thorough 
investigation of the interactomes of yeast65, E. coli66 and fruit fly67. The main drawback of AP-MS purifications 
is that it often requires genetic manipulation of the organism under investigation. Even though it has been 
successfully used in interactomic studies of genetically modified fruit fly68 and mouse69 the applicability of 
genetically engineered AP-MS cannot be extended to human studies due to obvious ethical reasons. 
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Figure 4. Protein affinity purification 
1. Co-immunopurification (Co-IP) enrichment is done 
using specific antibodies that recognize and bind the 
proteins of interest. The protein mixture is applied to 
immobile antibodies. The unbound proteins are 
discarded, the bound proteins along with the 
interacting partners is washed and then eluted. Co-IP 
can produce a high nonspecifically binding protein 
background. 
2. In protein complex isolation using tandem affinity 
purification (TAP), the protein of interest is tagged by 
genetic or chemical means. In the first step (A) 
sample is applied to first immobilized affinity 
material which binds the tagged protein from the 
first part of the affinity tag. The majority on 
nonbinding and unspecifically bound proteins are 
washed away and discarded. The tagged protein is 
eluted and applied to the second immobilized affinity 
material (B) that recognizes the second part of the 
affinity tag. Additional washes are used to remove 
remaining nonspecific proteins and finally the tagged 
protein along with its binding partners is eluted. The 
two step washing usually removes most 
nonspecifically binding proteins. 
1.2.5 Plasma depletion 
Blood plasma is a valuable diagnostic source for disease biomarkers and is commonly used in clinical diagnosis 
and research. The wide dynamic range of plasma protein abundances poses a challenge for MS-based 
research. Differences in in protein abundance range from serum albumin with approximately 50 mg/ml to 
interleukins with approximate concentration of less than 5 pg/ml covering a dynamic range of over ten orders 
of magnitude70. Usually the biomarkers for cancers and other maladies are mainly found in low-abundance 
protein category10. For this reason the low-abundance fraction of plasma proteins must be separated prior 
to MS analysis by depletion of the most abundant proteins. Clotting factors can be removed from plasma by 
normal clotting procedures to create blood serum. However, this is not enough to limit the dynamic range to 
MS tolerable level or to enable the detection of the low abundance protein fraction71. For depletion of plasma 
from the high and medium abundance constituents, several affinity purification methods have been 
developed72. Currently the most advanced depletion systems are able to remove fourteen of high abundance 
and further 45 medium abundance proteins from plasma or serum increasing the detection limits of low 
abundance proteins to less than one nanogram per milliliter levels73. However, a notable disadvantage in 
protein depletion is the removal of interesting proteins that are bound to albumin or other high abundance 
proteins74. Several peptides and proteins have been reported to be carried by albumin75 in the circulation so 
the removal of these high abundance components also eliminates the bound proteins from analysis. 
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2. Mass spectrometric analysis 
2.1 Ionization 
The mass spectrometers utilize electric fields to guide the molecules within the MS instrument (Figure 5.). In 
order for the molecules respond to electric fields, they must be charged. Several different methods are used 
to ionize the analytes such as chemical or thermal techniques; however, in proteomic MS the peptides are 
most commonly ionized by soft ionization methods MALDI (Matrix Assisted Laser Desorption/Ionization)76 or 
ESI25. Soft ionization method means that the ionization procedure is gentle enough so that it doesn’t 
fragment the peptides upon ionization. In MALDI the analyzed material, such as peptides or proteins, are 
deposited to solid surface along with matrix in water-solvent mixture and then allowed to dry. This causes 
the matrix and the analytes to co-crystallize to the surface. A short laser burst is then applied to the spot 
resulting in ablation of the matrix and the analyte to the gas phase. This leads to ionization of the analytes 
and entry to the mass spectrometer for analysis. 
Along with MALDI, electrospray ionization or ESI, is another widely used soft ionization technique. In ESI the 
solution with eluting peptides is pushed through an orifice with applied voltage. Due to the high pressure 
and the voltage, the eluting solution is dispersed into small droplets. These droplets undergo solvent 
evaporation with the aide of high temperature and gas flow on the ESI source. The evaporation concentrates 
the molecules and the charges in the droplets until the charge repulsion causes the droplets to fragment into 
smaller and smaller pieces in a series of Coulomb fissions. The pH of the ESI solvent also results in the charging 
of the analytes in the liquid phase. After several rounds of Coulomb fission and solvent evaporation, only the 
charged peptides are left in the gas phase and can then enter the mass spectrometer77. 
 
Figure 5. Overview of ESI ionization and hybrid quadrupole-time-of-flight (Q-TOF) mass analysis 
The peptides are first ionized by electrospray ionization. The charged peptides are guided by quadrupole mass selectors 
before entering time-of-flight (TOF) mass analyzer. Based on the flight time in the TOF analyzer the mass spectrometer 
is able to calculate the masses of each peptide. 
Using nanoliter flow rates in the nanoESI ionization the sensitivity and the ionization efficiency can be 
significantly improved allowing the detection of very low peptide quantities78. ESI is usually used with liquid 
chromatography separation due to the compatibility of the LC-solvents with ESI and MS. The LC-ESI interface 
is usually used on-line with MS machinery to inject the eluting analytes straight to the MS. This allows the 
automation of the analysis but also the characterization of the retention times of the analytes. One of the 
main benefits of ESI ionization is that it is capable of producing multiply charged peptides. This is a key factor 
in the analysis of large molecules but also aides in the fragmentation of peptides in MS/MS analysis79. The 
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propensity of ESI to generate multiply charged peptides can also be a disadvantage. The same peptide species 
can be present in few different charge states that complicate the data analysis. 
2.2 Common mass analyzers 
Mass analyzers are the core of mass spectrometers. They are used to concentrate, store, guide and separate 
the ion travelling within the mass spectrometer. Different types of mass analyzers have been developed with 
different benefits and drawbacks (Table 1.). Quadrupole mass analyzers use radiofrequency fields and 
electric currents to alter the flight paths of charged particles within the electric field. In the simplest case the 
quadrupoles pass all ions that enter the mass analyzer producing MS spectra. MS spectra contain all the ions 
that are detected at a given time and can be used to characterize the entire m/z range of the sample. By 
modulation of the electric fields, quadrupoles are also able to select molecules with specific m/z values to 
pass to the mass detector while discarding the rest80. Ion trap analyzers operate as quadrupoles but can trap 
and concentrate the ions for a brief period of time. This allows for higher sensitivity as the ion scan be 
concentrated prior to ejecting to detector. As with quadrupoles, the ion trap can be used to pass and detect 
all ions that are present or just a single ion with specified m/z. 
Table 1. Common mass analyzers and respective advantages and disadvantages 
Analyzer Advantage Disadvantage 
Quadrupole (single and triple) Relatively cheap, MRM capabilities (triple quadrupoles) Limited mass resolution and range 
Ion trap Good mass range, sensitivity, fast scan rate, low cost Limited mass resolution and dynamic range 
Time-of-flight High mass range, fast scan speed, good resolution and accuracy Limited dynamic range 
Orbitrap High resolution and mass accuracy Moderate scan speed 
FT-Ion cyclotron resonance Very high resolution and mass accuracy Very expensive, limited dynamic range 
 
The Fourier Transform – ion Cyclotron Resonance (FT-ICR) uses strong magnetic fields to trap ions. This is 
followed by frequency excitation causes the ions to move in a circular path to the detector which records an 
image current of the ions movement. This is transformed to mass spectrum using Fourier transformation 
algorithms. The FT-ICR mass spectrometers are highly accurate and have very high resolution but also come 
with a very high prize and size. Another mass analyzer that uses Fourier transformation algorithms to 
determine ion mass is the Orbitrap analyzer. Orbitrap captures ions around central spindle of the trap using 
electrostatic forces rather than magnets. The ions begin to orbit the central spindle but also begin to oscillate 
axially based on the m/z value. The image current of this m/z-dependent oscillation is detected and 
transformed to mass spectra81. Within the last decade, the high resolution and mass accuracy in combination 
with moderate price of Orbitraps have made them one of the most important MS tools in proteomics. 
In addition to Orbitraps Time-of-flight or (TOF) analyzers82 are frequently used in proteomic MS. TOF 
detectors work by measuring the time of ions travelling in the analyzer. When a group of ions arrive to the 
TOF mass analyzer they are first injected to the detector by small electric pulse by the pusher in to the 
constant electric field of the TOF analyzer where they are accelerated by constant electric field. The velocity 
of each individual ion depends on the m/z of the ion so that smaller m/z ions arrive to the ion detector faster. 
By measuring the time of arrival after the initial pulse, the exact m/z of each ion can be recorded and 
calculated83. The differences in the original kinetic energies of the ions with same m/z cause reduced of 
resolution in linear TOF analyzers. This can be corrected using reflectors in the TOF flight tube. Instead of 
linear flight path, the reflector curves the path of ions back towards the source in U-shaped trajectory. The 
depth that the ions enter the reflector depends on the velocity of the ion. Higher velocity ions penetrate 
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deeper and stay in the reflector a longer time while the slower ions take a shorter path and less time. This 
balances the initial differences in the velocity and allows the ions to arrive to the detector. The ions are finally 
detected using micro-channel plate (MCP) detectors that detect and multiply the signals which are then 
converted to mass spectra. 
The most efficient MS analysis is usually achieved using hybrid mass spectrometers. Hybrid MS equipment 
utilize several different types of mass analyzers. The use of various analyzers in conjunction can be used to 
bypass the inherent drawback of the analyzers thus increasing the resolution, sensitivity and mass accuracy 
of the MS analysis. Examples of hybrid MS instruments include Linear ion trap-Orbitrap, Quadrupole-ion trap 
as well as Quadrupole-TOF. 
2.3 Ion mobility separation 
In some cases the second fragmentation quadrupole can be replaced by ion tunnels that are used to trap and 
further separate the peptides. In one example the second quadrupole is replaced by the TriWave device that 
composes of ion trap, ion mobility separation (IMS) and transfer regions84. In IMS the ions travel through the 
IMS cell filled with gas. Instead of fragmenting the peptide, the IMS gas slows the velocities of the ions 
depending on their shape85. As a result the ions arrive to the detector at different times freeing the detector 
to scan the arriving ions with more precision and sensitivity. By separating the ion by their shapes, IMS creates 
and additional separation dimension for peptides with similar elution times in the liquid chromatography 
step prior to MS. The use of IMS separation step can increase the detection efficiency and sensitivity of 
peptides by almost 60% compared to normal separation allowing a much greater number of proteins to be 
identified in one single MS run86. IMS can also be used in separation of intact protein complexes87 and 
peptides with similar mass but with different shapes. These include glycan isoforms88 as well as analysis of 
structural variants of proteins85. 
2.4 Quadrupole tandem mass spectrometry 
In tandem mass spectrometry the ions are fragmented to produce smaller fragments which are then analyzed 
and used in sequence or structure elucidation of the original ion. Tandem mass spectrometry can be done in 
ion trap, TOF-TOF as well as quadrupole analyzers. In quadrupole tandem mass spectrometry two 
quadrupoles are used back-to-back (Figure 6.). In data dependent acquisition (DDA) the mass analyzers 
selects and passes only one single species of ions (or m/z values), called precursor ion, for collision induced 
fragmentation (CID) in the second quadrupole89. Quadrupole also records the mass of the precursor so that 
that the product ions can be traced back to this precursor for peptide identification. After passing the first 
quadrupole the precursor ions enter the second quadrupole where a curtain of inert collision gas, such as 
argon or helium, is applied. The ions that enter the gas filled chamber collide with the gas molecules causing 
the peptides to fragment. In CID the peptide fragments mainly from the amide bonds of the peptide 
backbone but in different positions of the peptide sequence90. This semi-random dissociation produces two 
species of product ions: one derived from the N-terminus (denoted as the b-ion) and one from the C-terminus 
(the y-ion) of the peptide. During the fragmentation the charge of the precursor peptide is either divided 
between the fragments or stays on one fragment while the other fragment acquires a neutral charge. Since 
charge is prerequisite for mass characterization of the ion, the ability to create multiply charged ion species 
is an advantage. The benefit of using trypsin as digestion reagent is that it creates a positively charged C-
terminus to the peptide as it cleaves after lysine or arginine. This enables one charge to remain in the y-ion 
after fragmentation as others may locate to the N-terminal b-fragments of the precursor. CID of large number 
of peptides with same sequence results in a series of product ions that differ in mass based on the site of the 
fragmentation. The mass differences between the product ions represent the differences in masses of 
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individual amino acids of the peptide sequence. In ideal case the fragmentation would produce a series of 
product ion have been fragmented after each amino acid generating a full series of b- and y-ions. However, 
this is rarely the case as some amino acids are more prone to fragmentation than others so the ion series 
pattern is generally dependent on the peptide sequence90.  
 
Figure 6. Overview of Q-TOF type mass selection and fragmentation 
The ionized peptides enter the first quadrupole which passes only one peptide for fragmentation and discards the rest. 
The second quadrupole fragments the selected peptide. The fragments enter the TOF detector that uses the fragment 
flight times to calculate the fragment masses. The fragmentation pattern of b- and y-ions of hypothetical peptide 
“PEPTIDE” is also shown. 
2.5 MSE tandem fragmentation 
MS/MS identification is limited by the possibility of fragmenting only few precursor ions during one duty 
cycle. It is estimated that a full tryptic digest of all yeast approximately 5000-6000 proteins can produce up 
to 300 000 different types of peptides91. Even though quadrupole-TOF mass spectrometers can fragment up 
to eight precursor peptides in one duty cycle of one second or less, the majority of the 300 000 are not 
analyzed and the sequence information is lost92. To overcome this limitation a data independent acquisition 
(DIA) method called MSE has been developed where all peptides enter the MS analyzer at the same time92 
(Figure 7.). The first pass of MSE analysis scans only the precursor ions that are eluted from the LC at a given 
time. In the second pass the same set of precursor ions is fragmented to produce a complex set of product 
ions. By repeating this cycle of precursor/product scans through the entire LC gradient, the mass 
spectrometer generates a chromatogram of eluting precursors and also of their fragmentation products. In 
order to combine the fragmentation information to correct precursor ions, the chromatogram and the 
fragmentation spectra is processed with bioinformatics tools. In processing of MSE data the program looks 
for the similar elution patterns of both the precursor and the fragment ions. When a perfect alignment is 
found between the retention times of precursor and product fragments the program links these product 
fragments to distinct precursors. Utilization of DIA methods such as MSE has the potential to improve the 
identification efficiency of proteins dramatically. For example, MSE study of tomato leaf proteome achieved 
over 350% increase in protein and almost 500% increase in peptide identifications compared to DDA 
method93. 
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Figure 7. Principle of Q-TOF type MSE identification 
In MSE identification the quadrupoles pass all peptides to second quadrupole. The second quadrupole cycles between 
low energy mode that keeps the peptides intact and high energy mode when all peptides are fragmented. The TOF 
records the masses of non-fragmented precursor ions as well as the fragment masses. The retention time for all masses 
is also saved. In the data processing step the algorithm matches the retention times so that the correct precursor-
fragment pairs can be linked. This enables the detection of significantly larger number of peptides than in normal DDA 
method.  
2.6 Data analysis of MS data 
The mass detector produces a raw file of the detected m/z values. Before analysis and peptide identification 
this file must be processed. Several different algorithms have been developed to clear the data from noise 
and to extract the detected ions from the raw files94-95. The resulting list of detected ions, their charge, 
retention time and the intensity of the ions is finally compiled in to one peak list. This peak list is the basis of 
mass spectrometric identification. 
2.6.1 Protein sequence databases 
Database-related protein identification is one of the main methods in proteomic research. The sequencing 
of the genomes of several species has produced a library of genetic information that can be computationally 
translated in to protein sequence information96,97. Several different public databases have emerged that offer 
the sequence information of different proteins from different species to be downloaded and used in MS data-
analysis98. One of the most notable proteomic databases is the UniProt/SwissProt database99. It contains 
protein sequences of almost 13 000 species and bacterial strains but also a reviewed database of manually 
validated protein sequences. 
2.6.2 Peptide mass fingerprinting 
The simplest way for peptide identification is peptide mass fingerprinting (PMF)100. In PMF the peptide 
masses are compared to a database of in silico calculated peptide masses of known protein sequences. If a 
match is found, the protein where the peptide ion originated can be identified with certain confidence. The 
problem with PMF is that there can be several different proteins that produce peptides with similar mass. 
This becomes an issue when the sample is complex or with low resolution mass spectrometers are used for 
PMF. For this reason PMF is used mainly in analysis pure protein solutions or of spots excised from 2-DE 
gels101. 
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2.6.3 MS/MS identification 
PMF identification relies just on the comparison of non-fragmented peptide masses to in silico digested 
masses but in complex samples additional round of search is needed101. In MS/MS search the second pass 
computationally fragments the in silico generated peptides to their respective fragment ions. When a match 
is found between the acquired precursor and computer generated ions, the fragmentation pattern on both 
are compared. If the patterns match, the program can statistically identify the peptide that has been 
fragmented and the protein where the peptide is derived from. The database-related search fails when an 
unknown or modified sequence is obtained. Mutations such as insertions, deletions or change of amino acids 
cause shifts in the precursor and fragment masses which cannot be identified when matching the observed 
spectra to the in silico generated mass list. Different search strategies102-103 have been developed to address 
this issue however, they suffer from sensitivity issues and high false positive rates104. 
MS analysis of post-translational modifications can be done using optional search parameters in the MS/MS 
identification. When performing the in silico digestion and fragmentation, the program adds the mass of the 
modification to the precursor ion and on all the fragments. This can then be compared to the observed mass 
spectra of the peptide and if a match is found, the peptide and the modification can be identified. The MS 
identification of PTMs requires that the exact mass of the modification is known and that the amino acid 
where the identification is attached is specified105. 
2.6.4. De novo identification 
De novo identification is a complementary method of peptide identification that can be used to bypass the 
constraints posed by database-related searching106. In de novo identification, the peptide sequence is built 
from the fragmentation pattern of the precursor peptide. Instead of comparing the obtained fragmentation 
pattern to the database generated spectra, the sequence is deduced from the mass differences between the 
fragment peaks. Even if the spectra does not produce a full peptide sequence, short stretches of the deduced 
sequence can be used in BLAST searches to identify the original protein107. The problem with de novo 
sequencing is that it is computationally labor-intensive and it requires good quality spectra for correct 
identification108. 
2.7 MS-based protein quantification 
One of the main improvements in the past few years in MS technology has been the extension of MS 
quantification capabilities. 2-DE gels have been the main method when comparing the expression differences 
of two samples but the limitations of the 2-DE system and in both detection and separation capabilities109 
have prompted researches to develop several MS-based solutions for global protein quantification110. These 
MS methods can be divided in to relative or absolute protein quantification. Relative methods are also further 
divided into labeled or label-free quantification. Absolute methods use added standard compounds to report 
the actual amount of peptides or proteins that are present in the sample while relative methods are used to 
compare two or more samples and to report the relative differences in quantities between them.  
2.7.1 Label-based relative quantification methods 
The labeling methods rely on the introduction of stable isotopes to the peptides to use in relative 
quantification. SILAC111 (Stable isotope labeling by amino acids in cell culture) is a widely utilized method in 
proteomic quantification. In SILAC the quantification is done metabolically by feeding normal, or “light” 
amino acids to the control cell culture (Figure 8.). In contrast, the experimental sample is supplemented only 
with isotopically labeled “heavy” amino acid, usually arginine or lysine, which is incorporated to the 
proteome of the cell line. When performing SILAC experiments lysates from the light and heavy samples are 
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pooled and analyzed with LC-MS. The incorporation of the heavy amino acids does not significantly alter the 
elution or other properties of the peptides. The only difference is the mass shift on the sample with heavy 
peptides caused by the isotope labeling and this mass difference can be used to separate the control from 
the experiment sample. The SILAC quantification is done by comparing the signal intensities of the precursor 
ions between the light and heavy labeled samples while the identification of the peptides is done from the 
fragmentation spectra of the respective precursor peptides. SILAC has been primarily used by labeling cell 
lines; however, the introduction of fully heavy labeled SILAC mouse112 and recently developed super-SILAC 
method113 have extended the use of SILAC to animal models and tissue samples. 
  
Figure 8. SILAC and ICAT labeling protocol 
SILAC quantification is performed by feeding 
isotope labeled, “heavy” amino acids to 
experiment cells. Control cells are fed with 
normal “light” amino acids. Both samples are 
prepared and then pooled and digested. In 
the MS analysis the light and heavy labeled 
peptides can be distinguished by the mass 
shift due to the heavy labeling. The SILAC 
quantification is made from the relative 
intensities of precursor ions and the 
identification from fragmentation spectra. In 
the ICAT method the samples are normally 
processed before being labeled. The control 
sample is labeled with “light” ICAT label 
while the experiment sample is labeled with 
“heavy” ICAT label. Similarly to the SILAC 
method, ICAT quantification is done using 
precursor intensities and identification from 
MS/MS spectra. 
 
 
 
 
Similarly to SILAC, the ICAT114 (Isotope Coded Affinity Tags) method uses two different isotope labels to 
distinguish between samples (Figure 8.). In contrast To SILAC the ICAT tags are attached to the proteins after 
lysis of the cells. The ICAT tag contains also a biotin component that is used in purification and enrichment 
of the tag containing peptides. The labeling is done by chemical attachment of the tags to cysteine. As with 
SILAC, the differentially labeled samples are pooled after digestion and the relative quantification is done 
based on the signal intensity differences of the two differentially labeled samples and identification from the 
product ion spectra. 
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The SILAC and ICAT methods use precursor spectra to quantify the peptides. Some methods employ the 
fragmentation spectra for both identification and quantification of the samples. As with ICAT, the iTRAQ115 
(Isobaric Tags for Relative and Absolute Quantification) and TMT116 (Tandem Mass Tag) tags are chemically 
attached to amino acids of peptides before the samples are pooled (Figure 9.). However, the tagging is usually 
done to peptides after digestion instead of intact proteins. The TMT and iTRAQ tags consist of three separate 
regions: the reactive group for attachment to free amine groups of the lysines and amino termini of the 
peptides, a mass balancer region and the actual reporter region from which the quantification is made. The 
design of the tags is such that each reporter ion has a mass difference of one Dalton. This mass difference is 
compensated by the balancer region so that the overall masses and other properties of the tags are identical. 
After labeling, the samples are analyzed with LC-MS. In the MS/MS the peptide is normally fragmented to 
produce the spectra for peptide identification. At the same time the isobaric tag is also fragmented to free 
up the reporter and the mass balancer regions. The balancer is discarded but the reporter ions are detected 
by the mass spectrometer. The relative quantification between samples is then done from the ratios of the 
reporter ion intensities. The benefit of the isobaric labeling strategy is that the mass of the precursors derived 
from different samples is the same due to the balancer region. Compared to SILAC and ICAT, this simplifies 
the MS data analysis and does not reduce the precursor ion intensity. It also enhances the sensitivity of the 
identification as the pooling of the samples adds to the amount of each tagged peptide thus increasing the 
precursor peptide intensity. Additionally the incorporation of the cleavable isobaric tags enables multiplexing 
of samples117. Multiplexing allows the analysis of up to eight samples simultaneously thus reducing the time 
and costs of the analysis118. 
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Figure 9. iTRAQ labeling protocol 
In the iTRAQ quantification samples can be 
multiplexed using iTRAQ labels with different 
reporter masses. The Samples are processed 
individually and labeled using different iTRAQ labels. 
After labeling the samples are pooled and analyzed 
with MS. Since the iTRAQ labels have isobaric 
masses the precursor scan shows only one m/z for 
peptides compared to two same precursors (light 
and heavy labeled) in ICAT and SILAC. The 
identification of peptides is made from MS/MS 
fragmentation spectra. Quantification in iTRAQ is 
made by comparing the dissociated reporter ion 
intensities in the low part if MS/MS spectra. Each 
reporter ion of certain mass represents one sample 
and can be compared to rest of samples to produce 
relative quantification of peptides and proteins. 
 
 
 
 
 
 
 
 
 
The problem with isotope labeling of peptides is that the labeling efficiency must be almost complete. 
Insufficient metabolic labeling of the heavy sample will show as an increase in the intensity of the light sample 
thus skewing the quantification. ICAT, iTRAQ and TMT may suffer from problems in the digestion and labeling 
efficiency of some samples that render the quantification unreliable. Additionally, iTRAQ and TMT can be 
contaminated by fragmentation of co-eluting peptides119. The mass window that passes the selected 
precursor to fragmentation for MS/MS may also pass other precursor ions with similar m/z. If two or more 
precursors are fragmented simultaneously, which may be the case with complex samples, the reliable 
quantification and identification is impossible. 
2.7.2 Label-free relative quantification 
Label-free quantification methods do not require derivatization of the samples prior to MS-analysis. Instead 
the quantification is done based on the amount of spectral matches to each protein or by the intensity of the 
eluting precursors120 (Figure 10.). Spectral counting (SC) utilizes the principle that the more abundant the 
protein, the more spectral matches it has on the MS/MS121. Methods for SC include protein abundance index 
Control 
samples
Experiment-1 
samples
Lyse cells and digest
Pool iTRAQ labeled samples
Lyse cells and digest
Label with 
iTRAQ label-1
Label with 
iTRAQ label-2
Experiment-2 
samples
Label with 
iTRAQ label-3
iTRAQ
MS analysis
Quantification 
from MSMS 
reporter spectra
Identification from
MSMS fragmentation 
spectra
1
2
3
1:2:2
1:1:1
3:2:1
MS2 MS2 MS2
MS1
Lyse cells and digest
 
 
27 
 
(PAI)122 and EmPAI123 (exponentially modified PAI). In PAI the approximate quantities of proteins in the 
sample are calculated by simply dividing the number of observed spectra with the number of calculated 
observable spectra. emPAI quantification modifies the PAI score by using only unique peptides and refining 
the quantification algorithm. 
 Figure 10. Principles of spectral counting 
and area under the curve methods 
In spectral counting the quantification is 
made by counting the number of MS/MS 
spectra for each peptide. In area under the 
curve methods the area of precursor 
chromatogram is integrated and 
quantification performed based on the 
total area under the chromatogram curve. 
In both methods the identification is made 
from the MS/MS fragmentation spectra. 
 
 
 
 
 
The PAI method has some inherent problems that may distort the quantification. Different physicochemical 
properties of peptides cause differences in peptide ionization which result in skewed quantification124. Also, 
low spectral counts from low abundance proteins or the saturation of detector by high abundance proteins 
and undersampling resulting from complex mixtures interfere with quantification125,121. In order to overcome 
these issues other spectral counting software and algorithms have been developed126,127 that have expanded 
the detection limits and accuracy of spectral counting quantification. 
Alternative way for SC is the quantification based on integrating the ion areas of eluting peptides or AUC 
(Area Under the Curve) methods128,129. AUC relies on the discovery that in ESI the signal intensity is 
proportional to the molar concentration of the analyte in the sample128. In AUC methods the peptide 
quantification is made by integrating the peak area of each eluting m/z and the identification is made 
simultaneously from the MS/MS fragmentation of the precursor. Quantification using AUC methods has been 
shown to be linear within the range of 10-1000 pmol and with dynamic range of four orders of magnitude129. 
The requirement of both quantification of precursor ions and identification from the MS/MS fragments poses 
difficulties in DDA-based AUC quantification130 in Q-TOF type MS instruments. An adequate number of 
precursor level data points must be gathered for reliable quantification but also the fragmentation spectra 
of the precursor must be good enough for identification of the peptide. Due to the limits in mass 
spectrometer duty cycle, the DDA methods often undersample complex data131. DIA methods can be used to 
circumvent the undersampling issues of DDA. As the precursor and product spectra are recorded 
simultaneously in DIA, enough data is collected for reliable quantification and identification. For example, 
MSE-based quantification using accurate mass and retention time pairs (AMRT) was shown to identify and 
quantify serum spiked proteins to 100 fmol level with an average quantitative variation below 15%130. 
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A drawback of the label-free methods is that multiplexing is not possible and the LC-MS analysis must be 
done one sample at a time. Quantification based on the comparison of different LC runs require also reliable 
chromatographic system that is able to deliver repeatable consecutive LC runs132. Current UPLC-level 
instrumentation can to produce good quality chromatographic separation in terms of separation, peak width 
and retention time stability to enable label-free quantification133. In addition to good quality 
chromatography, the bioinformatics tools must be able to process the data efficiently and with good 
precision. Adequate normalization of the data must be performed to account for the variations in injected 
sample amount or ionization. Also, the algorithms should include the different charge states of the same 
peptides for correct quantification132.  
Multiple reaction monitoring or MRM has been generally used in the quantification of metabolites but the 
developments in instrumentation and bioinformatics tools have allowed the method to be used also in the 
quantification of proteins134. MRM instrument is usually a triple quadrupole MS system (QQQ). Similarly to 
Q-TOF tandem mass spectrometer, two quadrupoles are placed back-to-back. The first selects the precursor 
ions which are then fragmented in the second quadrupole. In QQQ this is followed by a third quadrupole 
which is used to select certain fragments, known as transitions, which pass to the detector. The quantification 
is done by integrating the elution chromatogram for each selected precursor-transition pair. The main benefit 
of the MRM methods is its specificity and sensitivity135. As the precursor-transition masses are set beforehand 
with additional information of retention time and charge, the MS does not have to scan the entire mass range 
but only a small subset of the range. This frees up the duty cycle and allows the acquisition of more spectra 
per analyte. Also the requirement of identification of both precursor and transition masses allows for 
excellent specificity by eliminating majority of the unspecific precursors and fragmentation. The 
disadvantage of the MRM method is that the precursor-transition pairs must be known and set beforehand. 
In proteomics this requires the knowledge of the precursor peptide masses and the masses of the 
fragmentation products so analysis of unknown proteins that is not possible with MRM. The requirement of 
knowledge of precursor-product pairs before MRM analysis has been addressed by construction of 
proteotypic peptide libraries that contain the information of precursor masses of a variety of peptides and 
calculated fragmentation products136. 
2.7.3 Absolute MS quantification 
MS-based quantification can be used also for quantification of the absolute amount of proteins in the sample. 
The AQUA method137 relies on isotopically labeled synthetic peptides that correspond to the protein 
sequence that is quantified. A known amount of AQUA peptide is added to the digested sample and LC-MS 
is performed. The properties of the isotope labeled AQUA peptide and the normal peptide are the same, only 
difference is the mass shift from the labeling. Absolute quantification is done by comparing the ion area of 
the known amount of the AQUA peptide to the normal peptide. The problem with AQUA quantification is 
that it requires the synthesis of specific peptides so the quantification is feasible only to one or few proteins 
of interest. QconCAT138 is an extension of AQUA strategy. QconCAT is made using an artificial gene that 
contains the sequence of a number of peptides from different proteins that are under investigation. By 
adding a known amount of the isotopically labeled QconCAT protein to the sample prior to digestion and 
analysis, the absolute amount of proteins with corresponding sequences in QconCAT can be deduced. 
Label free methods can also be utilized in absolute quantification. Hi3 method is based on the observation 
that the top three most intense peptides per proteins reflect the absolute amount of each protein to a high 
degree139. Addition of a set of known internal standard peptides can be used to create a universal signal 
response factor which can be set as a reference which to compare the rest of the peptide intensities. This 
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method has been successfully used to quantify proteins in complex mixtures with a sensitivity of less than 5 
pmol/ml139. 
2.8 From MS data to biological interpretation 
Mass spectrometers are able to produce a wealth of information in terms of identification and quantification. 
Ultimately this experimental data must be put to context and translated to biological information. For this 
reason several ontologies describing biological processes and connections have been developed140. Most 
notable of these is the Gene Ontology (GO)141. GO is used to annotate each protein to a set of descriptions 
that best characterize the properties of the protein. The GO uses a preset terms as descriptions so that the 
same term can be annotated to several proteins that share a common property. In addition, the terms are 
hierarchically ordered so they can be classified in the terms of their more general parent terms. This general 
annotation and the hierarchical structure can be used in enriching a set of interesting proteins. If 
experientially acquired set of proteins enriches statistically to a certain GO term, a more general view of the 
biological phenomena can be acquired than just examining the proteins individually. Many ontologies have 
been developed that use different terms based on the context of the ontology142. For example disease 
ontologies are used to specify that set of proteins that have been experimentally linked to certain 
diseases143,144. On the other hand phenotypic ontologies can be used to associate genes and proteins to 
different phenotypic and anatomical traits145,146. 
To help the researcher to utilize the ontologies and to combine data from different disciplines in biology, 
several bioinformatics tools have been devised for enrichment and analysis. Simple gene enrichments to 
Gene Ontology can be done using Amigo tool147. For more in-depth analysis researchers can use DAVID 
Functional annotation tool148 or Ingenuity Pathway Analysis149 platform for functional enrichment and 
analysis of proteins in several different categories and ontologies. In addition to analysis, visualization of large 
amounts of data has proven to be invaluable for the interpretation of the data150 and programs like 
Cytoscape151can be used in construction, analysis and visualization of large networks of multifaceted 
biological data. 
3. Biomarker discovery 
One of the main goals of medical research is to transfer the acquired knowledge into clinical applications and 
biomarkers for known diseases. The term biomarker refers to measurable indicator of risk, existence, stage 
or response to treatment of specific diseases152,153. Biomarker can be almost any biological material that is 
found in the human body. Numerous genetic panels that test DNA sequences of known genes associated 
with diseases are commonly used in clinical diagnosis to evaluate the likelihood of acquiring the disease154. 
Metabolites and their intermediates are used in standard blood tests but also in diagnosis of cancers155 and 
congenital disorders156.  
In recent years the promise of new clinical protein markers for diseases has been great. Numerous early 
findings are characterized as “potential biomarkers”, however this promise has not been fully realized in 
terms of clinical practise157. Even though several protein biomarkers have been introduced to be used to test 
for diseases such as prostate158 and ovarian cancer159 the general amount of new clinical protein biomarkers 
has been low within the recent years157. The reasons for this may be due to lack of access to clinical patient 
material or the costs and effort required to transform initial discovery to validated clinical solutions153. 
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3.1 Biomarker categories  
Biomarkers can be divided into different categories based on the use of the biomarker152,160. Diagnostic 
biomarkers are used in screening and assessment of predisposition to certain diseases. The knowledge 
obtained from diagnostic biomarkers can be used in preventative medication or counseling in life style or 
nutrition. In most diseases and especially in cancer, the early diagnosis is of utmost importance161. Stage 
specific biomarkers that signal the early phases of cancer development before it has metastasized or matured 
into more malignant species can significantly improve the life expectancy of patients as therapy can be 
started in time. Additionally, progression of the disease can be assessed by analysis of stage specific 
biomarkers162 and the treatment adjusted accordingly. Special biomarkers related to drug response can be 
used to follow the effect of the treatment. Due to individual variations in drug metabolism same drug may 
not be suitable for all patients. In addition, heterogeneity of some diseases, such as cancer, may render drugs 
inefficient or cause adverse responses163 so the identification of biomarkers signaling drug resistance could 
be used to rectify the medication and improve prognosis. Finally, outcome biomarkers can be used to 
evaluate the result of the treatments but also to monitor the long term recurrence of the disease. 
3.2 From discovery to validation 
In biomarker research there are several different phases that need to be passed before marker can be 
declared clinically relevant and useful153. The search for biomarkers starts from discovery phase where 
control samples are compared to diseased samples. The discovery phase can be done in model systems such 
as cell lines and model organisms. From this comparison of control and diseased samples a list of differentially 
expressed candidate markers is obtained. However, this list still contains a large portion of false positives 
which must be distinguished from the true positive markers. The verification step narrows and confirms the 
list of candidates by more comprehensive analysis of markers by orthogonal verification of the findings. 
Verification is conducted using methods and material more resembling the final analysis and with more 
samples derived from a larger population to account for individual variation. After discovery and verification 
the biomarker enters the validation phase. In validation the found biomarkers and the developed 
methodology undergo a rigorous testing for sensitivity, specificity, repeatability, reproducibility, costs and a 
large variety of other parameters that must be passed for biomarker and method to qualify for clinical use164. 
3.3 Protein biomarkers 
Finding proteomic biomarkers for cancers and other diseases has been the goal of numerous experiments 
and studies152. The use of proteins as biomarkers is based on the idea that as the major workhorses of 
biological systems, diseases and other biological malfunctions may be reflected the proteomic level. For 
example, mutations in DNA can cause impairments in protein function or amount leading to cancer and other 
malignancies. Additionally, biological responses to diseases or injuries manifest often on the proteomic level 
so the discovery of biomarkers that signal these specific events would be extremely valuable (Figure 11.). 
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 Figure 11. Effects of disturbances in proteome 
The disturbances in proteome may be manifested in several ways. Mutations may cause changes to protein structure, 
abnormal post- translational modifications, disturbed protein-protein interactions and unnatural changes in protein 
expression. All of these can have a significant effect in many cellular pathways and networks. Unnatural proteomic 
changes may also contribute to the emergence of disturbances in other proteomic areas further complicating the search 
for suitable biomarkers for diseases. 
3.4 Source of protein biomarkers 
One prerequisite of clinical biomarker is that it can be readily acquired and analyzed. Blood is considered as 
a good source of proteomic biomarkers as it easily sampled and contains a huge variety of proteins ranging 
from normal circulatory proteins as well as condition specific transient proteins. Diseased and abnormal 
tissues shed and release proteins that normally would not be present in blood and these can be used as 
biomarkers for the diagnosis of the disease157. Analysis of protein biomarkers from blood suffers from high 
dynamic range of plasma proteins and the low concentration of the analyte biomarker. Even though the local 
concentration of the biomarker in close proximity of the diseased tissue is high, it is significantly diluted as it 
enters the bloodstream. Direct analysis of proximal fluids has been shown to be more sensitive than analysis 
from normal blood sample165, however the acquisition of the sample from proximal or interstitial166 fluids is 
more difficult that from normal blood sample taken from forearm. Other easily obtained fluids can also be 
used in biomarker detection. These include urine, nipple aspirate, cerebrospinal fluid and saliva. 
3.5 Mass spectrometry based proteomics in candidate biomarker discovery 
The role of mass spectrometry in proteomic biomarker discovery has been growing in recent decades. The 
ability to analyze samples globally and to create comprehensive lists of possible candidate biomarkers makes 
mass spectrometers excellent tools for the discovery phase of biomarker research167. Quantitative MS 
methods allow rapid identification but also allow comparative quantification of several hundreds of proteins 
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simultaneously. Multiplexing methods also allow the analysis of several different samples during a single MS 
run reducing the time, costs and inter-analysis variability110.  
3.5.1 Label-based MS quantification in clinical protein biomarker research 
Several studies on discovery-based proteomics have been conducted using protein labeling and MS-based 
quantification. SILAC method has been employed in studies of cancerous cell lines that have identified several 
potential biomarkers to distinguish cancerous tissue from healthy. Everley et al.168 compared the microsomal 
proteomes of two human prostate cancer cell lines with different metastatic potential using SILAC. Of the 
nearly 1000 identified proteins, 444 were quantified and of those 82 were shown to be significantly different 
between the cell lines. Another study by Kashyap et al.169 examined the differences between the secreted 
proteins of esophageal squamous cell carcinoma (ESCC) cell line and normal esophageal squamous epithelial 
cells with SILAC-based quantification and found 120 up- or downregulated proteins including several 
previously identified proteins with elevated abundance in ESCC cells. SILAC methodology can be applied to 
tissue samples by the recently introduced super-SILAC system113. In a study of cell cultures done from 
different phases of breast cancer tumor Geiger et al.170 used super-SILAC quantification to identify candidate 
biomarkers. These were then confirmed using super-SILAC on breast cancer tissue samples and based on the 
finding the team proposed six new candidate biomarkers for advanced breast cancer. 
The SILAC method requires direct labeling of living cells and cannot be applied to human subjects. However, 
labeling methods such as ICAT and iTRAQ are compatible for human studies and have been used to 
characterize the biomarkers in human serum. Kang et al. used ICAT to search for biomarkers of hepatocellular 
carcinoma (HCC) from the serum of liver cirrhosis patients171. They identified and showed the discriminatory 
power of alpha-1 acid glycoprotein as a marker for HCC in cirrhosis patients. A similar study was conducted 
from the urine of bladder cancer patients by Chen et al.172 identifying 55 differentially regulated proteins in 
cancer samples using iTRAQ. The accuracy of iTRAQ was further validated by analyzing Apolipoprotein A-1 
(APOA1) on ELISA demonstrating specificity and sensitivity of over 90%. The use of iTRAQ in tissue samples 
was exemplified by the analysis by Ralhan et al.173. They examined differences in tissue samples from head 
and neck carcinomas and healthy control tissues taken from a same patient. Several distinguishing proteins 
were identified and a panel of three proteins was shown to be able to separate the carcinoma from healthy 
samples with good sensitivity. Cerebrospinal fluid (CSF) is a rich source of biomarkers of diseases affecting 
the neurological system. In a study conducted by Lehnert et al.174 two proteins signaling the risk of Parkinson 
related dementia were identified with iTRAQ from CSF and then verified with MRM. Similarly, Kolla et al.175 
used plasma from pregnant women to search for candidate biomarkers for preeclampsia (PE). iTRAQ analysis 
was done from plasma taken from women with normal and plasma from women who developed PE. 
Quantification analysis revealed a list of altered proteins, including several known protein markers, which 
could serve as potential biomarkers for early stage PE.  
3.5.2 Label free methods in MS quantification of clinical protein biomarkers 
Even though the MS-based labeling methods have been proven useful in biomarker discovery the label free 
methods offer an alternative method of quantitative MS-analysis. Type-2 diabetes has been one of the most 
rapidly increasing metabolic diseases in the western world. Early diagnosis has the potential to reduce the 
costs and mortality of diabetes; however, an efficient and easy diagnosis method is still lacking. Saliva is an 
attractive source of biomarkers due to the availability and ease of procurement. To this end, Paturi et al.176 
used spectral counting to differentiate the proteomes of type-2 diabetic patients from healthy individuals. 
65 proteins were identified to be differentially regulated in diabetic patients. Category enrichment revealed 
several metabolism and immune response related proteins among the regulated proteins. These categories 
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have been previously reported to be associated with diabetes. In addition to identifying and verifying 
differentially regulated proteins, Paturi also demonstrated the increasing abundance of several identified 
proteins during the progression of diabetes highlighting the usefulness of saliva derived biomarkers in 
diabetes diagnosis and monitoring. 
The advent of high definition UPLC-MSE quantification has emerged as a promising technology in proteomic 
biomarker research. In an exemplary study of the Fabry disease Manwaring et al.177 identified urine 
Prosaposin (PSAP) as a candidate marker for Fabry disease using MSE-based quantification. The group also 
showed that the amount of PSAP decreased after 12 months of enzyme replacement therapy used to treat 
Fabry demonstrating the validity of PSAP in treatment monitoring. The added sensitivity and larger scale of 
shotgun type MS analysis has made it possible to characterize pathway-wide changes occurring in diseases 
and to assess the utility of different pathways as biomarkers. In a study conducted by Pizzatti et al. on chronic 
myeloid leukemia (CML)178 the proteomes of plasma from treatment responsive and resistant patients was 
quantified using MSE-based quantification. Ingenuity Pathway Analysis revealed altered lipid metabolism and 
Wnt pathway in the resistant patients. The identification of two interconnected pathways in treatment 
resistant CML can aide in the development of novel biomarker panels to stratify CML patients and to target 
the treatment more efficiently. Analogous study on primary open end glaucoma (POAG) was done by 
Pieragostine et al.179. They identified 27 differentially expressed proteins in tear fluid of POAG patients that 
could be used as predictive biomarkers. Pathway enrichment of these proteins indicated several 
inflammation- related proteins in the set of differentially expressed proteins confirming the earlier reports 
of the role of inflammation in glaucoma. 
3.5.3 MS detection of PTM biomarkers 
Differential post-translational modifications are also tempting targets in biomarker research. Some diseases 
may manifest in altered abundances of modified proteins that may be used as biomarkers. Potential disease 
PTM´s include phosphorylation, glycosylation, methylation180 as wells as acetylation181. 
Protein phosphorylation is the most common PTM in mammalian cells and controls several signaling cascades 
within the cell. As the cell signaling processes are often altered in cancer, the identification of abnormal 
phosphorylation in cancerous patients could be highly valuable biomarkers in diagnosis and treatment. The 
role of phosphorylation as biomarker is limited mainly to tissue samples or other cellular samples as it not 
generally found in secreted fluids such as plasma. In a study of the phosphoproteome of breast cancer cells 
using SILAC, Oyama et al.182 characterized the differentially modified proteins in control and resistant cells 
after stimulation. In addition, using a combined analysis of the phosphoproteomic and gene expression data 
the team identified a candidate phosphorylated biomarker that could be used to predict the relapse and 
survival of breast cancer patients. MS analysis of phosphoproteomics has been utilized also to search for 
biomarkers in early stages of Anthrax infection183. Manes et al. isolated the phosphopeptides from the spleen 
of mice in order to examine the early effects of Bacillus anthrax infection. 26 phosphopeptides were shown 
to be differentially regulated after 24 hours of anthrax exposure. If released in the circulation these 
phosphopeptides could serve as an early marker of anthrax exposure and subsequently as a sign for pre-
emptive medication. 
Studies have shown that cancer can have a major impact on the glycosylation pattern of several proteins184. 
Characterization of the altered glycoproteome has the potential to be a rich source of biomarkers in cancer 
diagnosis and treatment185. Glycosylation of Kallikrein 6 (KLK6) is altered in ovarian cancer and the can be 
used as biomarker for prognosis. However, the cancer produced KLK6 is masked by the normal production in 
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the central nervous system. In order to distinguish the normally found KLK6 from cancer derived protein, 
Kuzmanov et al.186 used mass spectrometry to identify differentially sialylated KLK6 that is exclusively derived 
from cancerous tissue. The differential glycosylation can be used to distinguish the cancer-related KLK6 from 
normally expressed protein and utilized as a prognostic biomarker of ovarian cancer. Characterization of 
global glycosylation patterns can also be used identify biomarkers. In a large study of eleven different breast 
cancer cell lines Boersema et al.187 identified 1398 unique glycosylation sites from the secretome of the cells. 
The team used lectin affinity enrichment and MS-based super-SILAC method to compare five different stages 
of breast cancer progression represented by the different cells lines. The team demonstrated that the 
amount of differentially glycosylated proteins changes during cancer development. They also demonstrated 
the usability of super-SILAC in human studies by comparing the cell line derived super-SILAC mixture to 
plasma from human subjects resulting in identification of several common peptides. 
3.5.4 MS identification of protein-protein interactions in clinical research 
Abnormal changes in protein-protein interactions are usually a symptom of a disease. For example viral 
infections can take over the cellular machinery for their own replicative purposes. Gene mutations may lead 
to alterations in physical interaction sites of proteins resulting in abnormal protein activity and harmful 
phenotypes188. Elucidation of these altered interactions may provide new insights into the mechanism of the 
disease but also in the search for candidate biomarkers and targets for drug intervention. 
HIV is one of the most devastating viral epidemics that have affected the world in the past decades. Even 
though HIV has been studied extensively, a cure to the disease is yet to be found. To expand the information 
of HIV in general and to identify candidate drug targets, several MS studies on the interactions of HIV proteins 
on host proteome have been conducted. Gautier et al.189 used immobilized HIV nuclear regulatory protein 
Tat as bait to capture the interacting proteins from T-cell nuclear protein fraction. They identified 129 
different Tat- interacting proteins that can be organized into different functional modules pertaining 
transcription activator and suppressors, chromosome organization factors and nuclear structure 
components. In a similar large scale experiment Jäger et al.190 utilized AP-MS to characterize the entire virus-
host interactome of HIV protein in Jurkat and HEK293 cells. In total 497 interactions were identified in several 
biological processes and cellular compartments. Of the 497 identified interactions only 19 had been 
previously characterized demonstrating the need for further characterization of HIV interactome. 
Oncogenes are a set of proteins that have the propensity to induce cancer191. Usually oncogenes are a 
product of gene mutation or alteration in the gene expression regulating mechanisms. The oncogene 
expression may manifest in altered protein-protein interactions resulting in rampant cell growth and cancer 
progression. Identification of these altered interactions can lead to potential drug targets and cancer 
treatment. To this end AP-MS experiments have been conducted using oncogenes as interaction baits. In 
order to characterize the interaction of cancer associated histone deacetylase HDAC1 in hepatocellular 
carcinoma cell line, Farooq et al.192 tagged HDAC1 with double affinity tag. 41 binding partners were identified 
of which 27 were novel interactors of HDAC1. Among the identified proteins were several members of cellular 
TCP1 and prefoldin chaperonin complexes. Similarly, Song et al.193 probed the binding partners of colorectal 
cancer oncogene APC using FLAG-affinity tagged APC. The team expressed tagged protein at endogenous 
levels identifying several known and novel interacting proteins.   
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AIMS OF THE STUDY 
 
Mass spectrometric methods and instrumentation have evolved significantly within the last decade. Novel 
techniques have been developed to tackle several different proteomic challenges. The goal of this work was 
to learn new MS methodologies and to use them to elucidate biological and clinical phenomena. The specific 
aims of were: 
- To use different mass spectrometric identification and quantification methods to elucidate the 
changes in biological processes after perturbation 
 
- To analyze different types of mass spectrometry generated proteomic data using various functional 
analysis tools and to generate meaningful biological and medical interpretations from the derived 
data and analysis results 
 
- To use the acquired knowledge of mass spectrometric methods and biological data analysis in order 
to search for novel biomarkers in clinical cases 
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MATERIALS AND METHODS 
 
The materials and methods are briefly displayed below. Full methodology and materials, including 
manufacturers and exact MS parameters can be found in the original publication or the accompanying 
supplementary information. 
 
Cell lines and strains 
 
The yeast cell line used in study I. was C-terminally TAP-tagged PSA1 (YDL055C) in W303 host strain. The 
HEK293 cell line for studies III. and IV. was FlipIn-293 that was transfected either with GREM1 expression 
vector (study IV.) or empty expression vector (study III.). 
 
Cell cultivations 
 
The yeast batch cultivation (study I.) was done in 30 l Braun Bioreactor at +30°C, agitation speed 800 rpm, 
airflow 1 l/min, and pH at 5.0. Verduyn (2X) was used as cultivation medium. Five liter samples were taken 
at 4, 8, 12 and 24 hours after beginning of cultivation. The cell density was calculated using OD600 
measurements. The mammalian cell lines (studies III. and IV.) were done on cell cultivation plates. In study 
III. the cells were treated by adding 30 mM N-acetylmannosamine to induce the production of sialic acid. 
Control cells were treated with similar volume of PBS. Induction was performed for 24 hour before sample 
processing. The GREM1 expression in study IV. was induced by adding 25 ng/ml of tetracycline to cells and 
then incubated for 24 hours. 
 
Plasma sampling 
 
Three patient plasma were sampled for study II. All patients were undergoing liver transplantation surgery 
for primary sclerosing cholangitis. 10 ml samples were drawn simultaneously during surgery from hepatic 
vein (hepatic sample) immediately after flush with portal blood before connecting the craft to the normal 
circulation, from portal vein (portal sample) and radial artery (arterial sample). Plasma was then separated 
from samples and then stored at -70°C. 
 
Protein preparation techniques 
 
The cells in study I. were lysed using mechanically by disruption of cells in bead beater in lysis buffer. Cell 
suspension was cleared using ultracentrifugation. The cells for protein quantification in study III. were lysed 
by adding cold lysis buffer to cells, incubating for 30 min on ice and snap frozen in liquid nitrogen. The cell 
samples for MRM-MS were lysed by incubation in 50% acetonitrile with added internal standard for ten 
minutes on ice followed by centrifugation to remove debris and then dried in Speedvac concentrator. Affinity 
purification samples for study IV. were lysed by incubation in lysis buffer. 
 
Protein concentration measurements were done using BCA method using Bovine albumin as standard. 
Plasma depletion for study II. was done using Agilent Multiple Affinity Removal column. The samples were 
injected to column and the flowthru collected. Three injections were made from each patient. 
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Affinity purification for study I. was done by applying the cleared lysate to IgG sepharose. The sepharose was 
washed and the protein complexes eluted by incubation with TEV protease at +16°C overnight. The flowthru 
was then applied to Calmodulin agarose for one hour at +4°C. The complexes were eluted using EDTA 
containing buffer. The purification for study IV. was done by passing the lysate through Strep-Tactin column, 
washing of the column and elution with biotin. The eluted GREM1 complexes were then applied to anti-HA 
agarose, washed and eluted using 0.2 M glycine. 
 
The proteins in studies I. II. and III were precipitated with TCA precipitation. The TCA concentration was 
adjusted to 25% and proteins were precipitated for 30 min on ice. Proteins were pelleted by centrifugation 
at +4°C for 30 minutes before washing with ice cold 0.1 M HCl in acetone using centrifugation. The washing 
step was repeated with ice cold acetone and similar centrifugation. The samples were briefly air dried and 
stored in freezer until analysis. The samples for proteomic quantification in study III. were done using 
commercial detergent removal resin. The samples were incubated in the resin for two minutes and eluted 
with brief centrifugation. 
 
The Western Blot validation in study III. was done using equal amount of samples in SDS-PAGE. Three control 
and three induced biological replicates were used. The proteins were first separated with SDS-PAGE and then 
transferred to PVDF membrane using semi-dry blotting. The membranes were blocked overnight with 2% 
BSA in PBS + 1% Tween20 at +4°C. Primary antibodies were anti ATIC (dilution 1:500), anti-NME2 (1:500) and 
anti-RAB5 (1:1000). Anti-beta Actin antibody (dilution 1:2000) was used as loading control. All antibody 
dilutions were done on PBS + 1% Tween20. Membranes were incubated in primary antibodies for 90 minutes 
at room temperature and then washed briefly three time with PBS + 1% Tween20 followed by three 10 
minute washes in same buffer. Polyclonal secondary antibodies were HRP-conjugated goat anti-rabbit (RAB5 
and beta Actin) and rabbit anti-mouse (ATIC and NME2). Washes for secondary antibodies were similar to 
first antibodies. The detection was performed using ECL Plus system and fluorescence detector. 
Quantification of proteins was done using ImageQuant TL and Excel software. 
 
Sample processing for MS 
 
Trypsin digestion in studies (II. III. and IV.) was performed by reducing the samples followed by alkylation of 
the free cysteines. The reducing and alkylation step was omitted in study I. Trypsin digestion was performed 
by digesting all samples overnight at +37°C. 
 
In study II. the peptides were labeled with iTRAQ 8plex kit according to manufacturer’s protocol. Labeling 
was performed for two hours followed by quenching with 10 µM ammonium bicarbonate for 30 minute at 
room temperature. The samples were then pooled and purified with SCX fractionation using cation-exchange 
cartridge. The bound peptides were washed and eluted using increasing KCl concentrations (5mM, 10mM, 
15mM, 25mM, 35mM, 50mM, 75 mM, 100 mM, 150 mM, 200 mM, and 350mM). The samples were dried in 
SpeedVac concentrator and stored in -20°C. 
 
The digested samples for studies III. and IV. were purified using C18 spin columns. The samples were applied 
to conditioned columns and washed. Elution was done using acetonitrile. The samples were then dried using 
Speedvac. 
 
 
 
 
38 
 
LC-MS 
 
The peptides in study I. were analyzed with Waters Micromass nanoLC CapLC on-line with QTOF Ultima 
Global mass spectrometer. The used trapping column was Waters Symmetry 300 (C18, 5 µm, 300Å, i.d. 
0.18mm × 23mm) and analytical column LC Packings PepMap100 (C18, 5 µm, 100Å, 75 µm i.d. × 25 cm). The 
gradient was done using 0.1% formic acid in acetonitrile as mobile phase A and .1% formic acid in 95% 
acetonitrile as mobile phase B. The gradient was from 95% mobile phase A to 5% in 600 minutes using 
variable flow technique at positive ion mode and data dependent acquisition. The LC-MS analysis for study 
II. was done using same LC set-up as study I. The gradient in study II was 95% of mobile phase A to 5% in 90 
minutes. The data was acquired at positive mode using data dependent acquisition. The LC-MS analysis in 
study III. was performed using Waters nanoACQUITY UPLC coupled to Synapt G2-S HDMS mass spectrometer. 
LC gradient was run from 3% phase B (0.1% formic acid in acetonitrile) to 30% over 140 minutes. 0.1 % Formic 
acid in H2O was used as mobile phase A. The used trap column was nanoACQUITY UPLC Symmetry C18 (180 
μm × 20mm, 5 μm) and nanoACQUITY UPLC BEH130 C18 (75 μm × 150 mm, 1.7 μm) as analytical column. 
Gradient was run at +30°C. Data was collected at data independent MSE acquisition method with positive 
polarity using IMS separation at 900 m/s. The LC-MS analysis in study IV. was done with nanoAcquity UPLC 
on-line with a Waters Synapt G2 mass spectrometer. Columns were identical to study III. and the gradient 
was from 3% to 40% mobile phase B in 90 minutes. Data was collected at data-dependent acquisition manner 
fragmenting eight peptides simultaneously using positive polarity. 
 
The LC-MS in the MRM-MS analysis in study III. was done using Waters 626 LC system on-line with Quattro 
Micro mass spectrometer. The used column was Synergi Fusion-RP 80A (250 mm × 2 mm, 4 μm) with flow 
rate 170 µl/min. The mobile phases were 0.1 % formic acid in H2O as phase A and 0.1 % formic acid in 
methanol as phase B. Gradient was run on stepwise manner for six minutes. Neu5Ac, ManNAc and labeled 
fructose were analyzed using negative mode. The MRM transitions for analytes were m/z 308.0 → 86.9 for 
Neu5Ac using collision energy 17 V; m/z 220.0 → 58.8 for ManNAc with collision energy 16 V and m/z 185.0 
→ 92.0 for labeled fructose with collision energy 9 V. 
 
MS Data analysis 
 
The raw data in studies I. II. and IV. was processed using Mascot Distiller software. In study II. the proteins 
were identified using X!Tandem and Lutefisk search engines. The identifications in study II. was done using 
Mascot search engine. The reliably identified peptide m/z-values were exported and used in MS runs of the 
same sample as exclusion lists to increase the number of peptide identifications. Mascot was also used to 
identify proteins in study IV. along with X!Tandem search engine. The protein identifications in study III. was 
done using Waters ProteinLynx Global Server search engine and protein quantification using Expression-E 
software. MRM quantification in study III. was performed with QuanLynx software and Excel. 
 
Functional analysis 
 
Gene ontology and KEGG analysis were used in study I. DAVID Functional tool was used in study III. using 
KEGG, Reactome, and Panther as limiting ontologies. Ingenuity Pathway Analysis was also used in study III. 
to characterize the functional changes. 
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RESULTS 
 
Study I. A combined database related and de novo MS-identification of yeast 
mannose-1-phosphate guanyltransferase PSA1 interaction partners at different 
phases of batch cultivation 
 
Model organisms are generally used as a starting point in many biological experiments. The ease of 
cultivation and manipulation enable a wide array of experiments that would not be possible using live animals 
or human subjects. In order to examine the interactomic changes as well as effects of enzyme limitation in 
database related MS identification and compare that to de novo identification, we analyzed the interactome 
of popular model organism Baker´s yeast Saccharomyces cerevisiae PSA1 protein during batch cultivation. 
PSA1 participates in yeast cell wall synthesis by catalyzing the conversion from mannose-1-phosphate to 
GDP-mannose. We chose to examine the effects of different cultivation conditions on the PSA1 interactome 
by tandem affinity purification from different points in batch cultivation. Time points (Figure 12.) were chosen 
to represent the end of initial lag phase and beginning of logarithmic growth (4h), mid-logarithmic growth 
(8h), end of logarithmic phase and beginning of nutrient limited growth (12h) and final time point 
representing starvation and very low growth (24h). 
The growth rate was monitored by measuring the optical density (OD600) during cultivation and calculating 
the growth rate (µ). The observed growth followed the expected sigmoidal curve of batch cultivated yeast 
population (Figure 12.). The growth curve also confirmed that the chosen time points represented the 
expected characteristics of population growth. 
 Figure 12. Yeast batch cultivation growth curve 
The growth curve showed predictable characteristics 
of batch cultivation. At four hour sampling point the 
cell are beginning the rapid growth phase. At eight 
hours the cell are rapidly dividing and the growth rate 
is high. After 12 hours the lack of nutrient begins to 
limit the growth and the cell must adapt to new 
situation. After 24 hours the nutrients are scarce and 
the cell have adapted to starving conditions. 
 
 
 
 
 
The protein identifications were made using database-related X!Tandem search engine194,195 with trypsin and 
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alignment. Using all three methods and time points we identified 235 distinct proteins with at least one 
peptide. All three identification methods performed similarly as X!Tandem-trypsin limited identified 106, 
X!Tandem with no enzyme 108 and Lutefisk-BLAST 112 different proteins (Table 2.). Out of the 235 distinct 
proteins 31 were identified with all methods. We then limited the search based on the amount of detected 
peptides. Using two peptides as detection limit, the overall number of all detected proteins fell to 74 with 58 
identified with X!Tandem-trypsin, 35 with X!Tandem no-enzyme and 24 with Lutefisk-BLAST. Three peptide 
limit further reduced the overall number of detected proteins to 43 with 38 found with X!Tandem-trypsin, 
29 with X!tandem no-enzyme and only seven with Lutefisk-BLAST. 
We then analyzed the proteins that were identified with at least two peptides with Gene Ontology, KEGG 
Pathways and Intact Protein Complex database. Largest detected category was ribosomal proteins. Of the 92 
identified proteins 62 were ribosomal. Non-ribosomal proteins contained proteins involved in energy 
producing pathways, amino acid and lipid biosynthesis, cell signaling and cell wall morphology. Even though 
PSA1 is a cytoplasmic enzyme, several mitochondrial and nuclear proteins were also identified. 
Comparison of identifications between time points revealed that 21 unique ribosomal proteins were 
identified in the four and eight hour time points. At 12 and 24 hour time points the number of ribosomal 
interaction partners for PSA1 fell to 11 (12h) and 10 (24 hours). In non-ribosomal proteins most interaction 
partners were found at eight hour time point with 21 identifications. Non-ribosomal PSA1 interacting 
proteins for 4 hour, 12 hour and 24 hour time points were 12, 12 and 16 proteins respectively. 
We finally assessed the sensitivity of our study by comparing our data with known interaction partners for 
PSA1 obtained from Saccharomyces Genome Database (SGD) (Table 2.). Out of all 74 known PSA1 interaction 
partners we were able to identify 18 in our set of one peptide limit protein hits. Out of these nine were found 
with all methods, 16 with X!Tandem trypsin, 15 with X!Tandem no-enzyme and 11 with Lutefisk-BLAST. When 
the peptide limit was set to two, X!Tandem-trypsin identified 13, X!Tandem no-enzyme nine and Lutefisk-
BLAST six SGD reference proteins. In the most stringent analysis of three or more proteins the number of 
Lutefisk-BLAST reference identification fell to only three proteins, while the X!Tandem no-enzyme identified 
seven and X!Tandem trypsin ten proteins. 
Table 2. Number of protein identifications of PSA1 binding partners in peptide limited sets by different search methods 
and comparison to reference set of known 74 PSA1 protein interactions. 
Identifications 
X!Tandem-
trypsin 
X!Tandem-no 
enzyme Lutefisk 
 Total number of 
identifications 
One peptide limit 106 108 112  236 
Two peptide limit 58 35 24  74 
Three peptide limit 38 29 7  43 
      
Number of known 
interactions 
X!Tandem-
trypsin 
X!Tandem-no 
enzyme Lutefisk 
 
 
One peptide limit 16/74 15/74 11/74   
Two peptide limit 13/74 9/74 6/74   
Three peptide limit 10/74 7/74 2/74   
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Study II. Relative quantification of several plasma proteins during liver 
transplantation surgery. 
 
Organ transplantation involves many phases that can influence the success of the operation. The 
procurement, storage, actual transplantation and following reperfusion can cause damage to the craft that 
may eventually lead to malfunction and loss of the craft and patient. The prognosis and treatment would 
significantly benefit if early markers of poor outcome could be identified. In order to characterize the 
proteomic changes occurring during transplantation surgery we analyzed the plasma proteomes of three 
individuals using iTRAQ labeling method and mass spectrometry. The plasma samples were drawn from 
arterial systemic circulation, portal vein that supplies blood to the liver and hepatic vein that carries the blood 
from the liver (Figure 13.). Sampling was performed early during the reperfusion to represent the initial 
phases of reperfusion-related plasma changes. 
Figure 13. Plasma sampling and 
significantly changed proteins. 
Hepatic/arterial ratio represents 
differences between arterial and 
hepatic proteins, portal/arterial 
represents change across 
intestines and hepatic/portal 
differences occurring within the 
liver 
 
 
 
 
 
 
Generally the plasma samples taken from hepatic vein had approximately 30% lower protein concentration, 
average 53.6 mg/ml, than samples from portal vein or artery, average 76.4 mg/ml and 74.5 mg/ml 
respectively. In order to reduce the wide dynamic range of the plasma we removed six high abundance 
plasma proteins (albumin, IgG, IgA, transferrin, haptoglobin and antitrypsin). The depletion step removed on 
average 70% of the protein content from the samples. 
Remaining plasma proteins were then digested and labeled with iTRAQ labeling kit. In order to reduce the 
sample complexity, the labeled samples were fractionated off-line by strong cation exchange (SCX). An 
exhaustive MS analysis was done on all the fractions by running each sample twice. After identification, an 
exclusion list was created from all the identified m/z values and new MS run was performed on the same 
samples. By excluding the identified peptides we were able to expand the number of identified peptides 
significantly as the first exclusion run identified on average 28% novel peptides compared to the no-exclusion 
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run. The second exclusion produced an additional 10% increase in peptide identification results proving the 
benefit of sample mining through repeated exclusion runs. 
The total number of identified proteins in all patient samples and repeat MS runs was 72. 53 of the identified 
proteins are found in the list of top 150 of most abundant plasma proteins196 highlighting the limitations in 
sensitivity of the used methods and MS machinery. Of the 72 identified proteins 31 could be also quantified. 
The overall change in abundance was generally rather low as only ten proteins passed the 10% significance 
limit. 
The examination of the over ten percent changed proteins in the portal to hepatic comparison revealed five 
proteins that had reduced in abundance within the liver (Figure 13). These included Histidine-rich 
glycoprotein (HRG), Antithrombin-III (SERPINC1), Fibrinogen alpha chain (FGA), Apolipoprotein E (APOE) and 
Beta-2-glycoprotein 1 (APOH). The largest reduction was observed with HRG as the amount decreased by 
almost 30% within the liver. Three proteins were found to increase over ten percent. Alpha-1-acid 
glycoprotein 1 (ORM1) was increased by 15%, Inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4) increased 
by 20% and Alpha-2-macroglobulin by almost 25%. The comparison of hepatic plasma to arterial plasma 
showed very similar changes to the hepatic to portal sample. Eight out of ten significantly increased proteins 
were common to both, only APOE and APOH displayed smaller than ten percent change (approximately -4% 
in APOE and ~-8% APOH). The changes observed in portal to arterial plasma was less pronounced as only two 
proteins, Serum paraoxonase/arylesterase 1 (PON1, +16%) and Angiotensinogen (AGT, +12%) were found to 
change more than ten percent. 
Study III. Label-free mass spectrometry proteome quantification of human 
embryonic kidney cells following 24 hours of sialic acid overproduction 
 
The main benefit of label-free quantification is that it does not require sample derivatization prior to MS runs. 
This eliminates the inevitable loss of sample during processing steps. In order to view the functional changes 
caused by extensive sialic acid, N-Acetylneuraminic acid (Neu5Ac), production in mammalian cells, we utilized 
high resolution mass spectrometry and label-free protein quantification in proteome analysis of in embryonic 
kidney cells. The peptides were analyzed using ion mobility separation, MSE fragmentation and then 
quantified with Expression-E label-free quantification method. We also monitored the levels of Neu5Ac and 
ManNAc by multiple reaction monitoring MS (MRM-MS).  
 
We induced the production of Neu5Ac by adding a 30mM ManNAc to the cell culture media. The ManNAc 
and Neu5Ac levels were measured prior to induction, 15 and 30 minutes after and hourly for the first six 
hours. Final measurement was done 24 hours after ManNAc addition. We saw no change in the levels of 
Neu5Ac or ManNAc in the non-induced control samples. However, the ManNAc level began to rise 15 
minutes after induction. Intracellular ManNAc stabilized after one hour to approximately 2.7 times that of 
the zero-hour sample. After 24 hours the ManNAc level had increased to approximately 4.8 times higher than 
the original zero-hour sample. The Neu5Ac level did not show significant increase in the first 30 minutes but 
began to rise after one hour. The levels continued to rise almost linearly and were had risen approximately 
70-fold after 24 hours in induction. 
 
The proteomic changes occurring after 24 hours of induction were examined using label-free MS 
quantification. All samples were done using three biological replicates and all samples were run three times 
to ensure good technical reproducibility. Prior to quantification the quality of MS-data was assessed. The 
 
 
43 
 
mass accuracy of runs was approximately 1 ppm. The retention time and intensity errors in detected ions 
between runs were on average 5.1% and 0.8% respectively. The number of identified peptides that were 
found in three technical replicates was on average 58% and 72% on at least two replicates. Overall the quality 
of data was judged good enough for label-free quantification. 
 
In all the biological and technical replicates we were able to identify altogether 1802 distinct peptides with 
at least one good quality peptide. Out of these we were able to quantify 1193 in at least two biological 
replicates. 105 proteins were shown to be significantly up- or down-regulated (>1.3 fold regulation). Out of 
these only seven were up- and 98 were down-regulated. The MS quantification results were verified with 
Western Blot analysis of three representative proteins. 
 
We then performed functional analysis of the set of 105 changed proteins using Gene Ontology enrichment, 
DAVID functional analysis and Ingenuity Pathway Analysis tool (IPA). Several categories were identified in the 
set of changed proteins. These included Protein transport, Plasma membrane, Signal transduction, Small 
GTPase, Golgi apparatus, Metabolic pathways of S-adenosylmethionine as well as Purine and Pyrimidine 
biosynthesis pathways and Remodeling of cellular adherens junctions. IPA analysis also revealed two 
interconnecting pathway clusters among the significantly changed proteins. One network contained several 
signaling pathways related to cytoskeletal organization, cell-cell contact and Remodeling of adherens 
junctions. Other interconnected network contained cell cycle, apoptosis and protein synthesis- associated 
categories. 
 
In order to characterize the protein-protein interactions among the changed proteins, we downloaded all the 
interactions of all the 105 significantly changed proteins from PINA database197,198. This resulted in a list of 
2421 interacting proteins and 4539 interactions. This list was filtered to include only those interactions 
occurring between the changed set. This resulted in 40 proteins and 47 interactions including proteins sharing 
functional similarities such as ribosomal, proteasome and spliceosome proteins. 
Study IV. Gremlin-1 associates with fibrillin microfibrils in vivo and regulates 
mesothelioma cell survival through transcription factor slug 
 
Analysis of model organisms is usually one of the first steps in biomarker discovery. Cell lines derived from 
diseased tissues can be examined to elucidate the mechanism behind the disease. Normal cell lines can also 
be manipulated in order to investigate the effects in cellular functions. In affinity purification the interaction 
partners of specific proteins are studied by expressing the affinity tagged protein in cell lines. The acquired 
interactomes of proteins can reveal interesting new biological functions but also the role of the proteins in 
diseases and other abnormal states. In a study of Gremlin-1 (GREM1), a cytokine inhibiting the functions of 
bone morphogenic factors, the interactome of GREM1 was investigated using affinity purification mass 
spectrometry. The findings were then validated in primary cell cultures from aggressive mesothelioma cell 
line and patient derived tumor tissue samples. 
 
The interactome of GREM1 was purified using tandem affinity purification method and analyzed with high-
resolution mass spectrometer. The interacting proteins were identified using Mascot and X!Tandem search 
engines. The use of two search strategies improves the reliability of the identifications as the algorithms are 
different and can be considered as orthogonal methods. The final list of GREM1 interactions composed of 
twelve proteins that were found in all three biological replicates and using both search engines. 
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The tagged GREM1 was transfected to the FlipIn HEK293 cell line using stable insertion to genome with an 
inducible tetracycline promoter. However, even with small induction, the amount of tagged GREM1 may be 
considerably higher than the native form resulting in unspecific interactions. Additionally, the tag itself or 
purification material may bind some proteins that will produce false positives in the results. For this reason 
we filtered the list of acquired interactions with those proteins that were identified from mock purification 
done using the cell line that was transfected with the tag-containing expression vector. 377 distinct proteins 
were found to bind the tag or purification material. These were removed from the identified GREM1 
interactions resulting in a list of four different interacting proteins. These included Cytokeratin-9 (KTR9), 
Cytokeratin 2a (KRT2), APOBEC1-binding protein 2 (DNAJB11) and Fibrillin-2 (FBN2). Fibrillin-2 was identified 
in all three replicate experiments and at least with two peptides in two replicates. 
 
The interaction between GREM1 and FBN2 was further investigated with surface plasmon resonance 
technology suggesting a strong interaction between the proteins. Additional colocalization and -expression 
assays in primary mesothelioma cell lines and tumor tissues also confirmed association with GREM1 and 
FBN2. 
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DISCUSSION 
 
Database dependent search engines have become the default protein identification methods in proteomic 
mass spectrometry199. Several different algorithms have been developed to identify the peptides and their 
respective proteins from complex mixtures. In this work we utilized several database dependent search 
strategies, including Mascot94, X!Tandem194,195 and Waters ProteinLynx Global Server (PLGS) to identify 
proteins from mammalian and yeast cells as well as human plasma. In general the database dependent 
methods are quite straightforward. The proteins are purified, digested with trypsin and then analyzed with 
MS2. However, some samples require extensive sample handling prior to MS analysis. The dynamic range of 
plasma proteins and the especially the overrepresentation of albumin in plasma can significantly reduce the 
number of identification by charge competition and other ion suppression effects28. In a study of proteomic 
changes in plasma during liver transplantation surgery we depleted six high abundance proteins from plasma 
samples removing approximately 70% of the proteins content. In order to further reduce the complexity of 
the samples prior to the MS we fractionated the digested peptides using strong cation exchange to eleven 
fractions. Samples were then analyzed with LC-MS/MS and Mascot search engine to identify the proteins. 
Overall we were able to identify 72 proteins in all patients, which is a rather low number of identifications 
considering the complexity of plasma10. One reason for the lack of proteins identification could be that the 
original depletion step was not adequate enough to reduce to number of high abundance proteins that mask 
the lower abundance peptides in the MS. Additionally, the limitations in detection sensitivity of the used, 
limited performance mass spectrometer has the potential to limit the detection to only the high abundance 
fraction of the plasma proteome. 
A complementary way of database related identification is de novo peptide sequencing. Deciphering of 
peptide sequence from spectra can be used to bypass the dependence of known sequences in database 
related protein search106 but also to add confidence to the data if used in conjunction with other identification 
methods. We used database–related search engine X!Tandem and Lutefisk de novo sequencing algorithm to 
investigate the changes in yeast PSA1 protein during various points of batch cultivation. We tested the effect 
of enzyme limitation to protein identifications by setting the search parameters to trypsin digested peptides 
and also setting the parameter to all possible peptides with no specified digestion enzyme (Table 2.). The 
quality of the PSA1 binding partner identifications was also examined by observing the effects of limiting the 
number of detected peptides in protein identification. The identification results when the identification was 
limited to only one detected peptide, produced almost equal number of proteins identifications in X!Tandem 
trypsin- limited, X!Tandem no-enzyme limitations and Lutefisk searches. However, as the peptide limit was 
raised to two or three the number of the quality differences between the methods became more evident. 
X!Tandem trypsin identified the highest number of proteins in both sets while the number of Lutefisk 
identified proteins fell almost 80% in two peptide limited search and 93% in three peptide limited set. 
X!Tandem no-enzyme identified approximately 30% less proteins in both peptide limit sets than X!Tandem 
trypsin. Such comparison illustrates that the traditional database-related methods still exceed de novo 
identification methods in the identification efficiency. Also, the use of specific enzyme limitation is extremely 
beneficial as it limits the search space of the search thus reducing the processing time but also improves the 
identification efficiency199. However, the use of de novo method is not without merit. In the one peptide 
limited search we could identify 31 proteins with all three methods. Such combined use of two totally 
different search algorithms can increase the confidence in the protein identification since it is unlikely that 
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the both algorithms will identify the same random peptide. This becomes valuable especially in the low 
abundance proteins that are often found by only one peptide. 
The added confidence in identification can be achieved also by using two database-related search engines200. 
Even if the basic principle of protein identifications is the same, the algorithms that are used to detect and 
score the identified proteins are different so the two search engines can be considered as complementary 
methods201. The need for more rigorous filtering criteria and validation is particularly evident in interaction 
studies as they have a tendency to contain a number of false positive results arising from nonspecific binding 
either to the proteins themselves or the material that is used in the complex isolation58. Therefore the 
validation of identifications and removal of false positives is crucial especially in cases where specific 
biomarkers for diseases are being examined. In the study of biological functions of lung cancer related202,203 
GREM1 in mesothelioma, we examined the interactome of GREM1 using AP-MS in HEK293 model cell line 
using two database-related search engines, Mascot and X!Tandem. We used stringent criteria and 
background filtering scheme to limit the identification to true positives. The criteria included detection in all 
biological replicates with good peptide hits on both search engines. We also performed a background protein 
subtraction using a list of proteins that were identified in AP-MS analysis of non-tagged cell line. Four proteins 
passed our criteria, including Fibrillin-2 (FBN2). FBN2 is a structural part of extracellular microfibrils that 
regulate the bioavailability of several growth and morphogenic factors such as BMP- 2, -4 and -7204,205 which 
are also shown to bind and be inhibited by GREM1206,207. Even though we used stringent filtering criteria with 
the MS results to limit the results, the interaction between GREM1 and FBN2 was further examined using 
surface plasmon resonance technology. The results confirmed the strong physical interaction between 
GREM1 and the N-terminal peptide of FBN2. In order to examine the interactions in vivo, the expression and 
localization of GREM1 and FBN2 was monitored in cultured primary mesothelioma cells and in tumor tissue. 
In mesothelioma tumor biopsies the GREM1 and FBN2 staining patterns were very similar suggesting strong 
colocalization. Additionally, gene expression analysis of primary mesothelioma cell line revealed strong 
expression of both GREM1 and FBN2 further confirming the association between these two proteins. This 
work clearly illustrates the utility of AP-MS in targeted discovery type biomarker research where novel targets 
of diseases are being studied. Even though the exact mechanism and functions of GREM1 and FBN2 in 
mesothelioma need further elucidation, information obtained from this interaction experiment may greatly 
aide in future mesothelioma biomarkers search. 
Database-related search engines identify the peptides by comparing the observed spectra to theoretical in 
silico digested spectra and calculates the probabilities of the detection95. In high background samples or low 
intensity spectra the identifications may be incorrectly assigned producing a false positive identification or 
rejection of true positives. In the liver transplantation plasma quantification experiment we used iterative 
strategy of excluding detected peptides from subsequent searches to increase the number of detected 
peptides. Based on the first MS run we assigned those m/z values with good peptide identification to 
exclusion lists. The same sample was then run again with MS/MS exclusion list, this time fragmenting only 
those peptides that were not identified in the first run. By using several rounds of this run and exclude- 
strategy and combining all of the peak lists in the final Mascot search, we were able to significantly expand 
the number of identified peptides and add confidence to our protein identifications. 
One of the major goals of this work was to learn and utilize mass spectrometric quantification in biological 
samples and to examine that data in biological and clinical context. To this end we used iTRAQ labeling 
method115 and label-free quantification130 to assess the proteomic changes in human plasma and cellular 
lysate. In an experiment to learn more about the changes occurring in liver during liver transplantation, we 
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labeled depleted plasma samples from three sampling points representing blood flow to and from liver and 
gut with iTRAQ (Figure 13.). Even though we used extensive sample fractionation and several MS runs 
including exclusion lists, we were able to identify altogether only 72 distinct, mostly high abundance 
proteins196 and quantify 31 of those with confidence in all samples. Of the 31 quantified proteins only ten 
showed changes larger than 10%. Of the ten proteins that were changed more than ten percent five were 
reduced in abundance within liver. Four of these, (Histidine-rich glycoprotein HRG, Antithrombin-III 
SERPINC1, Fibrinogen alpha chain FGA, Beta-2-glycoprotein-1 APOH) are related to blood coagulation208-209. 
Additionally Beta-2-glycoprotein (APOE) was found to be consumed by the liver. APOE functions as a part of 
lipoprotein particles mediating their removal by hepatocytes so the clearance in the liver represents the 
normal liver functions210. Three proteins increased in abundance within liver. These included Alpha-1-acid 
glycoprotein (ORM1), Alpha-2-macroglobulin (A2M) and Inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4). 
ORM1 and ITIH4 are both acute phase, liver produced proteins211,212. ORM1 functions as a general transporter 
protein in the plasma but also as a modulator of immune system during acute-phase213. ITIH4 has been linked 
to acute phase response in trauma and has been shown to increase during acute ischemic stroke and 
surgery214,211. A2M is a high abundance protein that functions as general plasma proteinase inhibitor215. In 
general our data suggests that the coagulation cascade is activated within the craft in the very early phases 
of reperfusion. Simultaneously acute phase proteins are released from the liver in response to the trauma 
from the surgery. The quite small number of changed proteins could be due to the fact that the samples were 
taken from the very first rinse of the portal blood in the craft and the full proteomic effects have not had the 
time to occur. Alternatively, the reason could be that the levels of high abundance proteins are very unlikely 
to show major fold changes. A massive increase or reduction in the levels of several high abundance proteins 
could alter the osmotic balance of the blood leading to disruptions in humoral homeostasis and functions. 
Conversely, the low abundance proteins could exhibit much larger changes in response to trauma without 
affecting the major humoral proteomic status. However, due the sensitivity limitations of the used MS 
instrument and possibly insufficient sample fractionation216,119 we were unable to characterize the low 
abundance fraction of plasma 
One problem with iTRAQ is that the labeling protocol requires several handling and fractionation steps that 
may cause sample loss and unreliable quantification. Label-free quantification offers an alternative, more 
straightforward way of MS-based protein quantification. We utilized label free protein quantification to 
examine the effects of excess sialic acid production in N-Acetylmannosamine (ManNAc) induced HEK293 
cells217 (Figure 14.). Exogenous ManNAc has been shown to induce the production of sialic acid in mammalian 
cells218, sialic acid in turn is generally used as terminal glycan in many glycoproteins48. The excessive 
production of sialic acid was quantified and verified using multiple reaction monitoring mass spectrometry 
(MRM-MS). With the added sensitivity of UPLC level separation, MSE-based fragmentation and ion mobility 
separation we were able to identify over 1800 distinct proteins from HEK293 cells. We quantified the proteins 
using label-free, area under the curve Expression-E method116. Altogether we quantified the relative changes 
of 1193 different proteins in at least two biological repeats. The added sensitivity and resolution of the newer 
MS instrumentation can be clearly illustrated by comparing the iTRAQ results and Expression-E 
quantification. The iTRAQ experiment was performed on a limited resolution and sensitivity LC-MS system 
limiting the identification and quantifications to tens of proteins. On the other hand, the Expression-E 
experiment was done using state of the art MS instrument with high precision liquid chromatography. The 
effect of high pressure liquid chromatography has been shown to significantly increase the peptide 
separation and subsequent MS identification efficiency133. Additionally, in Expression-E experiment we 
utilized IMS separation84 that further separates the ions within mass spectrometer thus allowing more 
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peptide to be detected and identified. Fragmentation using DDA methods can significantly limit the number 
of identifications219 but also bias the identifications to the high abundance proteins of the sample220,3. In the 
plasma work where identification was limited to high abundance proteins, the fragmentation was done using 
DDA. In contrast, the Expression-E experiment used MSE method to fragment all eluting peptides thus 
expanding the dynamic range and number of detected proteins. 
The biological data obtained using MS can be divided in to two categories. Global proteomic experiments 
characterize the behavior of multitude of proteins in different states as targeted experiments focus more on 
the characteristics of individual or a selected group of proteins. A part of the targeted proteomic research is 
the study of protein-protein interactions. In the study of the interaction partners of yeast GDP-mannose 
producing enzyme PSA1221 in various points of batch cultivation (Figure 12), we identified major changes in 
the amount of ribosomal proteins binding to PSA1. The first two sampling points, representing time of high 
growth, showed the highest number of ribosomal protein binding totaling of 21 unique proteins. After 
reaching the limits of growth due to limitation in nutrients in the final two time points the number of 
ribosomal PSA1 binding proteins halved. Non-ribosomal proteins were seen to vary also throughout the 
cultivation. We identified proteins of plasma membrane functions, biosynthesis machinery, cellular signaling 
and energy production- related categories. Based on our data the interaction landscape of the PSA1 protein 
is quite dynamic. During the early phases of cultivation and time of rapid growth, the biosynthesis of PSA1 is 
high due to the high demand of proteins of cell wall synthesis of rapidly growing and budding cells. This may 
be reflected on the number of ribosomal proteins binding to newly synthesized PSA1. In the latter time points 
the growth is slow so the synthesis of PSA1 is diminished leading to reduced number of interacting ribosomal 
proteins. Similarly the interactions to non-ribosomal proteins vary based on the cultivation phase. As a key 
player in the cell wall synthesis machinery221,222 PSA1 could influence the rate of cell wall synthesis by altering 
the direct interactions to other proteins participating in cell wall synthesis. It may also modulate other 
systems indirectly by binding and affecting signaling proteins or directly with interactions to proteins of 
biosynthetic processes and energy production. The dynamic nature of PSA1 interactome may be the reason 
for the rather low sensitivity when comparing to known PSA1 interactors. Only 18 out of 74 known PSA1 
binding proteins were identified in the experiment. This low number could be due to false negatives resulting 
from missed MS detection of low stoichiometry proteins or loss of binding partners in sample processing 
steps. Additionally, the differences may be a result of different cultivation conditions in the reference set as 
we showed that the interactions are strongly dependent on the state of the cultivation and possibly other 
environmental factors. Even with the limitations in sensitivity, our experiment showed that AP-MS- 
identification and interaction analysis of samples can bring new information about the behavior of proteins 
in different phases of cultivation. 
The global proteomic experiments produce a wealth of data of numerous proteins. Examination of each 
individual protein is not enough to create a full systemic picture of cellular events so analysis is often done 
using different ontologies140. When examining the effects of sialic acid overproduction in HEK293 cells we 
analyzed the data using several different ontologies. In our study we identified 105 proteins that were found 
significantly altered after induction of sialic acid production with N-Acetylmannosamine. Interestingly 100 of 
those proteins showed down-regulation and only seven up-regulation. The reason for such bias towards 
down-regulated proteins may be that cells adapt to the stress resulting from increased sialic acid 
concentration by down-regulating certain cellular systems rather than initiating new processes by protein 
up-regulation. To view the exact processes that were affected we analyzed the resulting list of 105 changed 
proteins using ontologies such as Gene Ontology, DAVID functional analysis tool and Ingenuity Pathway 
Analysis. Several enriched categories were identified. One of the main findings was that the protein transport 
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category was clearly enriched as we identified 16 proteins in that category. Among the proteins annotated 
to protein transport category were several small GTPase proteins. Small GTPases are used in targeting cellular 
transport vesicle and also in organelle identification purposes223-224. A set of these small GTPases are also 
associated with Golgi apparatus. Golgi contains the glycosylation machinery and is the ultimate destination 
of CMP-activated sialic acid so the proteomic changes relating Golgi apparatus are not unexpected. Another 
strongly enriched category was Remodeling of Adherens Junction category. Plasma membrane bound 
adherens junctions mediate cellular contacts between adjacent cells using E-cadherin protein225. E-cadherin 
has been shown to contain sialic acid226 so excess cellular sialic acid could alter the sialylation state of E-
cadherin resulting in remodeling of the junction to adapt to the new situation. We also identified select 
metabolic and cellular proliferation related categories in the changed set of proteins. The physical 
interactions between the changed proteins were examined by downloading all known interaction from PINA 
database198,197. 47 interactions were identified between 40 of the changed proteins including several 
proteasomic, spliceosomic and ribosomal proteins. Taken together our data suggests that overproduction of 
sialic acid alters the transport of cellular cargo within the cell (Figure 14.). Increased flux through glycosylation 
machinery has been shown to affect the cell surface protein glycosylation pattern227,228 so the changes 
observed in the protein transport machinery could be the result of this altered trafficking to the cell surface. 
One possible target of the differentially glycosylated proteins is the cellular adherens junction and its resident 
E-cadherin. Excess sialic acid in E-cadherin could result in disturbed cellular contacts and subsequent 
remodeling of the adherens junction contact points. Simultaneously the cell proliferation and metabolic 
processes are regulated to adapt the stress caused by abnormal sialic acid levels. Additional studies are still 
warranted to verify and further characterize the results; however, our experiment demonstrates the usability 
of global MS protein quantification and ontology-based analysis in deciphering complex cellular processes. 
 
Figure 14. Effect of ManNac induction and sialic acid overproduction. 
After induction with 30mM N-Acetylmannosamine the cellular sialic acid levels increased over 70-fold. This may lead to 
accumulation of excess sialic acid and subsequent incorporation to glycoproteins. The transport of these proteins to cell 
surface leads to changes in cell-cell contacts. The cells then try to adapt to the new situation by changing the cellular 
tranport routes and cellular adherens junctions. Additionally select metabolic routes are affected by the increase in sialic 
acid content.  
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CONCLUDING REMARKS AND FUTURE PROSPECTS 
 
In this project we utilized mass spectrometry methods in proteomic research. We analyzed the global 
proteomic patterns of human plasma and model cell line as well as characterized the proteomic changes 
occurring after perturbations using two different mass spectrometric quantification methods. We also used 
several protein identification algorithms to identify protein-protein interactions from mammalian cells and 
Baker´s yeast. In the interaction experiment involving yeast PSA1 proteins we showed that the physical 
protein-protein interactions vary considerably depending on the stage of the batch cultivation. We also 
demonstrated the applicably of combined use database dependent and de novo protein identification 
methods in mass spectrometric proteome research. Similarly, in the study to decipher the interaction 
partners of lung cancer related GREM1 protein, we used two database dependent search algorithms to limit 
the results to true positives. One of the identified proteins was FBN2. The interaction with GREM1 and FBN2 
in vitro was confirmed by surface plasmon resonance. In vivo experiments also showed strong co-localization 
and co-expression of GREM1 and FBN2 in primary cell lines and tumor tissue. This type of AP-MS 
identification of novel binding partners clearly demonstrates the benefit of targeted MS analysis of disease 
related proteins in basic functional characterization of these proteins but also in search for novel disease 
biomarkers. 
 
The developments in quantification methodology of mass spectrometers have had a significant effect in large 
scale proteomic research. In this work we utilized label-based iTRAQ quantification to elucidate the changes 
that occur in human liver during transplantation. We employed rigorous fractionation of samples and 
multiple rounds of exclusion MS runs to identify 72 distinct plasma proteins. Ten of these showed abundance 
changes of more than ten percent. The results indicate that coagulation cascade is activated within the 
transplanted craft immediately upon reperfusion. The liver consumes but also secretes several proteins 
related to coagulation and acute phase response. The data obtained could be used as a starting point for 
expanded studies to find biomarkers for craft rejection as well as in patient prognosis. In addition to label-
based methods we used high resolution mass spectrometry and label free MS quantification to examine the 
proteomic effects of excess sialic acid production in mammalian cells. After 24 hours of sialic acid 
overproduction we were able to show significant abundance changes of 105 proteins. Functional ontology 
analysis of the changed proteins showed reduction in cellular protein transport, select metabolic and 
signaling pathways and in the organization of cellular adherence junctions. The analysis of this type 
demonstrates the capabilities of simple, large scale quantitative MS analysis in decoding the larger functional 
processes in model biological systems but also the possibilities of such MS-analysis in novel biomarker 
discovery in clinical cases. In combination with external data such as interaction databases, gene expression 
repositories and other data sources the obtained MS data can significantly improve the analysis of cellular 
systems and generate information that could not have been done without the use of these high throughput 
methods. 
 
This work was carried out during a time when the developments in mass spectrometric instrumentation and 
data processing tools have increased the amount of biological information tremendously. The ever increasing 
sensitivity and resolution of mass spectrometers and evolving bioinformatic solutions will surely continue to 
add to the already vast amount of data available. At the same time the gene expression, genetic sequence, 
metabolic, phenotype and other -omics data has seen a similar increase in abundance creating a wealth of 
data for public use. Combining all this data will provide deeper insight in the biological processes under 
investigation but also a deeper understanding of the complexity of entire biological systems. The challenge 
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for future biologist is in how to decipher the multitude of data resulting from these systems biology analyses 
and in how to translate that in to relevant clinical solutions. 
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